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ABSTRACT 
KELLY MCGOWAN: Targeted PRINT® Nanoparticles for Effective Cancer Therapy 
(Under the direction of Joseph DeSimone) 
 
Conventional therapeutics for the treatment of cancer are often faced with 
challenges such as systemic biodistribution within the body, drug degradation in vivo, 
low bioavailability at the site of disease, and off-target toxicity.  As such, particulate drug 
delivery systems have been developed with the aim of minimizing these limitations of 
current therapies.  Through the PRINT® (Particle Replication in Non-wetting Templates) 
technology, hydrogel nanoparticles, prepared from biocompatible poly(ethylene glycol) 
and acid-sensitive silyl ether crosslinkers, were functionalized and conjugated with 
targeting ligands for the folate receptor (FR), HER2 receptor, and transferrin receptor 
(TfR).  By conjugating specific ligands to nanoparticles to impart specificity, highly 
selective targeting and internalization (>80%) of nanoparticles were demonstrated in 
various cancer cell lines.  The extent of cellular uptake of targeted nanoparticles was 
dependent on the surface characteristics of the nanoparticles, particle concentration, and 
kinetics.  Because a negative surface charge reduces nonspecific cellular uptake, 
attaching monoclonal antibodies to the surface of negatively charged PRINT 
nanoparticles facilitated specific binding of the antibodies to cellular surface receptors 
that subsequently triggered receptor-mediated endocytosis.  Additionally, the multivalent 
nature of nanoparticles influenced cellular uptake.  Specifically, nanoparticles with a 
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higher valence internalized more rapidly and efficiently than those with a lower valence.  
Nanoparticles that selectively target and accumulate within diseased cells have the 
potential of minimizing drug degradation under physiological conditions, enhancing 
bioavailability at the tumor, improving the efficacy of the drug, and reducing toxicity 
from systemic biodistribution. 
Drug delivery through targeted nanoparticles was achieved by loading 
nanoparticles with silyl ether-modified gemcitabine prodrugs.  Covalently reacting the 
prodrug into the nanoparticle matrix minimized drug loss, while the acid-sensitive silyl 
ether moiety enabled release of gemcitabine at a low pH.  Targeted nanoparticles 
appeared to accumulate intracellularly, through TfR-mediated endocytosis, within acidic 
vesicles whose environment could trigger degradation of the prodrug and thus, release of 
gemcitabine.  Leveraging the specificity of targeted nanoparticles and acid-sensitive silyl 
ether-based gemcitabine, targeted nanoparticles (IC50 = 1.8 × 10-2 nM) were far more 
potent than free gemcitabine (IC50 = 4.1 × 104 nM).  Therefore, this system demonstrates 
the tremendous potential of targeted PRINT nanoparticles as advanced drug delivery 
agents. 
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 CHAPTER 1 
ENGINEERING PARTICLES AS POTENT DRUG DELIVERY SYSTEMS 
 
1.1  Designing Nanoparticles as Cancer Therapeutics 
Conventional chemotherapeutic drugs are effective in the treatment of cancers but 
also have limitations.  They are distributed nonspecifically throughout the body, affecting 
both normal and cancerous cells.1  This lack of specificity and thus bioavailability 
decreases the efficacy of the drugs.  However, toxicity to normal tissue limits the dose 
and frequency of treatment.  Thus, nanotechnology has been employed to address these 
issues for therapeutic drug delivery.2  Several parameters, such as particle size, shape, 
modulus, surface charge, surface chemistry, and drug release, must be considered in the 
rational design of drug nanocarriers and are discussed below. 
 
1.1.1  Nanoparticle Therapeutics 
Through nanotechnology, researchers have developed methods for improving the 
therapeutic efficacy and functionality of cancer treatments.3  Some extensively 
researched nanovectors include nanoparticles,4 liposomes,5 dendrimers,6 and micelles7 
(Figure 1.1). 
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Figure 1.1  Examples of nanocarrier systems for drug delivery: (A) nanoparticles, (B) 
liposomes, (C) dendrimers, and (D) micelles.  Adapted from [8]. 
 
Liposomes are spherical, self-assembled colloidal vesicles produced from lipid bilayers 
with an inner aqueous phase.  The lipids consist of a hydrophilic head and a hydrophobic 
tail.  They are appealing as nanocarriers because of their general biocompatibility, 
biodegradability, and amphiphilicity.9  Both hydrophilic and hydrophobic molecules have 
been incorporated into liposomal strategies with success.  Doxil and Myocet are 
liposomal formulations of the chemotherapeutic doxorubicin and are approved for the 
treatment of metastatic breast cancer, ovarian cancer, and multiple myeloma.10-12  
DaunoXome is daunorubicin formulated within liposomes and is indicated as a 
therapeutic for advanced HIV-associated Kaposi’s sarcoma.13 
Micelles are another class of lipid-based nanocarriers.  Commonly prepared from 
amphiphilic block copolymers, micelles are self-assembled closed colloidal structures 
that consist of a lipid monolayer with a hydrophobic core and hydrophilic shell.14  The 
hydrophilic outer region stabilizes the hydrophobic core while rendering the system 
soluble under aqueous conditions.  The hydrophobic core serves as a reservoir for 
hydrophobic or water-insoluble drugs.15  By this approach, Genexol-PM and NK105 are 
(A) (B) (C) (D) 
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currently in clinical trials as polymeric micelle formulations of paclitaxel for the 
treatment of various cancers, including breast, pancreatic, and gastric cancer.16,17 
Dendrimers are synthetic, branched macromolecules of nanometer dimensions 
(average diameter of 1.5-14.5 nm) with arms that extend radially from a central core.18  
They are biocompatible, monodisperse, multivalent, highly water soluble, and possess a 
modifiable surface.6,19  Polyamidoamine dendrimers are one of the most commonly used 
platform in this area and have demonstrated improved efficacy as cancer treatments over 
free systemic drugs such as cisplatin and methotrexate.20,21  Dendrimers can be 
conjugated with targeting molecules, imaging agents, or drugs for multifunctional drug 
delivery systems, but they require numerous synthetic steps, which can be difficult to 
translate into large-scale production.8,18,22 
Nanoparticles have also been explored as pharmaceutical vehicles for cancer 
therapy.  While they can be prepared from organic and inorganic materials, polymers are 
among the most common scaffolds for nanoparticles.  Synthetic polymers, such as N-(2-
hydroxypropyl)methacrylamide copolymer (HPMA), poly(ethylene glycol) (PEG), and 
poly-L-glutamic acid (PLA), have been conjugated to therapeutics for polymer-drug 
conjugates.23,24  They can be formulated to incorporate hydrophobic or hydrophilic cargo, 
both small molecule drugs and macromolecules such as nucleic acids and proteins.25-27  
Nanoparticles can also be tailored to release therapeutic cargo at a controlled rate in a 
time- or condition-dependent fashion.28-30  The surface of nanoparticles can be 
functionalized to influence in vivo circulation and accumulation at the target site.31,32  
Naturally occurring polymers, such as albumin, chitosan, and heparin, have also been 
utilized to deliver chemotherapeutic drugs.1  For example, Abraxane is a nanoparticulate 
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formulation of paclitaxel in which the drug is bound by albumin.  It is approved for the 
treatment of metastatic breast cancer and is being investigated in clinical trials for the 
treatment of other cancers including non-small-cell lung cancer.33,34 
 
1.1.2  Particle Size and Shape 
The size of particles plays an important role in biodistribution in vivo and 
mechanisms of cellular internalization.  Most studies have investigated the effect of size 
with spherical particles.  Nanoparticles in the size range of 10-100 nm are generally 
accepted as effective drug delivery agents, determined by in vivo clearance and 
biodistribution.  Particles less than 5-10 nm are typically cleared rapidly from circulation 
through renal clearance,35,36 and larger particles up to around 15 µm generally collect in 
the liver and spleen and are removed from circulation by the reticulo-endothelial system 
(RES).37,38  Kupffer cells in the liver are actively involved in removal of particles, as well 
as mechanical filtration of particles by sinusoids in the spleen.39 
Particle size is also a key factor in the mechanism of cellular internalization.  
Particles can be internalized into cells through phagocytosis, macropinocytosis, caveolae-
mediated endocytosis, or clathrin-mediated endocytosis.40-42  The mode of particle entry 
into cells influences subsequent intracellular microenvironments of the particle.  
Understanding the mechanism of internalization allows particles to be engineered to 
accumulate in particular intracellular regions for site specific triggers or drug delivery. 
As the field of nanomedicine continues to advance, the shape of particles is 
emerging as a key factor in biodistribution and cellular internalization.  It has been 
reported that prolate elliposoids can effectively attach to macrophages but are not well 
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internalized.43,44  Also, the geometry of interaction between the particle and cell is critical 
to inducing or inhibiting internalization.  Tangent angles of the particle at the point in 
contact with macrophages must be less than 45° for particle internalization.45  
Furthermore, filomicelles, filamentous particles with lengths up to 18 µm, have been 
reported to circulate in vivo for up to one week whereby the circulation time correlated 
with the length of the particle.46 
 
1.1.3  Particle Modulus 
The modulus of particles is another significant factor in designing particulate drug 
delivery systems that has not been thoroughly investigated.  One study reported the low 
uptake of soft polyacrylamide beads (1-6 µm) by macrophages while their rigid 
counterparts were readily phagocytosed.47  They found that the soft particles frustrated 
actin filament formation by macrophages, thereby preventing internalization.  Conversely, 
another report of rigid liposomes decreased complement activation and thus, reduced 
internalization by macrophages.48  This area requires additional research but has shown to 
be an important parameter for consideration in designing therapeutic particles. 
 
1.1.4  Particle Surface Charge 
The surface charge of particles can influence cellular internalization and in vivo 
circulation.  Generally, positively charged particles are efficiently internalized by cells 
because of electrostatic interactions between the positively charged particle surface and 
the negatively charged cellular membrane.49,50  Particles with a positive surface charge 
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also undergo more phagocytosis by macrophages and accumulate in the liver and 
spleen.51,52  Conversely, particles with negative surface charges typically exhibit low 
cellular internalization.53  It has also been reported that negatively charged particles can 
circulate longer in vivo and thus, better accumulate in the tumor.54 
 
1.1.5  Particle Surface Chemistry 
Surface properties of particles influence their interactions with proteins and cells 
in vivo.  Poly(ethylene glycol) (PEG) is often conjugated to the surface of particles to 
impart stealthing properties in circulation.  PEG reduces adsorption by serum proteins, 
minimizes nonspecific cellular uptake, and decreases phagocytosis by macrophages, 
thereby extending circulation time in vivo.55  In addition to prolonging circulation within 
the body for accumulation of particles in the tumor, selective interaction with cells is 
important.  It is desirable for particles to specifically internalize into cancerous cells so as 
to deliver therapeutic cargo to the site of interest, thereby maximizing drug efficacy while 
minimizing any adverse side effects.  Thus, targeting ligands are conjugated to the 
surface of particles to promote cellular internalization at the disease site.56 
 
1.2  PRINT Particles as Cancer Therapeutics 
The PRINT (Particle Replication In Non-wetting Templates) technology is a 
robust particle fabrication approach that facilitates independent control over particle size, 
shape, matrix composition, and surface chemistry.  It has been described previously57-64 
and is illustrated in Figure 1.2.  Photopolymerizable low surface energy prepolymers, 
 7 
such as perfluoropolyethers, are used to generate elastomeric molds that replicate features 
on a silicon master produced by photolithographic techniques.  These molds become the 
template for the fabrication of particles prepared from proteins,59 monomers,58,60-64 or 
polymers.57  A preparticle solution is applied to the PRINT mold, provided by Liquidia 
Technologies, with a sheet of poly(ethylene terephthalate) (PET).  The mold and PET are 
laminated together under pressure to fill the cavities in the mold with the preparticle 
solution.  As the sheet of PET is separated from the mold, excess preparticle solution is 
effectively removed from the mold because of the higher surface energy of the PET, and 
thus, enables the formation of individual particles.  Solidified particles can then be 
transferred to a sacrificial adhesive layer for collection. 
 
 
Figure 1.2  Schematic illustration of the PRINT process. 
 
Through the PRINT platform, a variety of particles (Figure 1.3) have been 
fabricated to investigate the rational design of particles for delivery of therapeutics.  
Particles of different shapes and sizes from 80 nm to 20 µm, composed of biocompatible 
polymers such as poly(ethylene glycol) (PEG), poly(D-lactic acid), and proteins, have 
been fabricated.57,59,62  Additionally, particles were prepared from novel silyl ether-based 
materials and disulfide crosslinkers to produce stimuli responsive nanocarriers for 
advanced drug delivery.61,65  PRINT particles have also been readily loaded with 
chemotherapeutic drugs and imaging agents as therapeutic and imaging particle 
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systems.61,65-67  Furthermore, particle surfaces have been modified for specific targeting, 
imaging, and enhancing in vivo circulation.63,68  Through the PRINT process, various 
factors in engineering model particles as drug delivery vehicles have been investigated 
and will be discussed below. 
 
 
Figure 1.3  Diverse array of hydrogel (unless noted otherwise) particles fabricated 
through the PRINT platform.69 
 
1.2.1  Particle Size and Shape 
Employing the PRINT technology and its independent control over particle shape 
and size, hydrogel particles over a range of sizes (100 nm to 5 µm) and shapes (cylinders 
and cubes) were fabricated, and the interdependent effect on internalization in HeLa cells 
was investigated.58  Generally, large microparticles internalized more slowly than smaller 
nanoparticles, with 3 µm and 5 µm cubic particles internalizing minimally in HeLa cells.  
HeLa cells internalized more cylindrical particles (~75%) with diameters of 500 nm and 
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1 µm (h = 1 µm for both particles) than 2 µm cubic particles (~45%).  For the 
nanoparticles, cylindrical nanoparticles with dimension of d = 150 nm and h = 450 nm 
(aspect ratio, AR = 3) internalized most rapidly and effectively.  Despite a similar volume, 
the more symmetric, low AR, cylindrical counterparts (d = 200 nm and h = 200 nm, AR 
= 1) were internalized more slowly.  Cylindrical nanoparticles with a diameter of 100 nm 
and an AR of 3 were also internalized more slowly than nanoparticles with a diameter of 
150 nm and AR of 3 (Figure 1.4).  This demonstrates that the internalization kinetics of 
nanoparticles by HeLa cells is dependent on both the size of the particles and the shape 
(elongated, rod-like vs. symmetric cylinder). 
 
 
Figure 1.4  Internalization of PRINT particles into HeLa cells at 15 µg/mL and 37 °C up 
to 4 h.  Legend depicts particle dimater and volume.58 
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Internalization of these hydrogel particles by HeLa cells was mostly mediated by 
a combination of clathrin and caveolae pathways (Figure 1.5).58  Prior to incubation with 
particles, HeLa cells were incubated with various biochemical inhibitors of energy-
dependent processes, clathrin-mediated endocytosis, caveolae-mediated endocytosis, and 
macropinocytosis.  Inhibition of cellular uptake by cells pretreated with sodium azide/2-
deoxyglucose (NaN3/DOG) suggests that all particles are internalized through an energy-
dependent process.  Decreased uptake of particles was observed for cells preincubated 
with cytochalasin D (cyto D), an inhibitor of macropinocytosis/phagocytosis and also 
clathrin- and caveolae-mediated endocytosis.  In the presence of inhibitors for clathrin-
mediated endocytosis, Dynasore, chlorpromazine, and genistein, cellular uptake of 
cylindrical nanoparticles (150 nm, AR = 3 and 200 nm, AR = 1) decreased markedly.  
For 1 µm (AR = 1) particles, only chlorpromazine significantly inhibited uptake of the 
particles.  Although the mechanism of internalization is unclear for larger particles, 
nanoparticles are clearly internalized, in part, by clathrin-mediated pathways.  In the 
presence of inhibitors for caveolae-mediated endocytosis, β-cyclodextrin (MβCD) and 
genistein, internalization of nanoparticles was affected more significantly than uptake of 
microparticles, which was expected as caveolae generally can only endocytose particles 
in the range of 50-100 nm.70  This work suggests that clathrin- and caveolae-mediated 
endocytosis, and to a lesser extent, macropinocytosis are all involved in cellular uptake of 
nanoparticles and microparticles.  These mechanisms appear to play a larger role with the 
internalization of 150 nm (AR = 3) and 200 nm (AR = 1) nanoparticles.  Nonetheless, 
none of the biochemical inhibitors that were studied inhibited particle internalization to 
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>95%, suggesting that the possibility of non-clathrin- and non-caveolae-mediated 
mechanisms of internalization. 
 
 
Figure 1.5  Internalization of PRINT particles into HeLa cells preincubated with various 
inhibitors of endocytosis.58 
 
1.2.2  Particle Modulus 
Modulus is a factor for consideration in the design of particles for cancer therapy.  
It has not been extensively explored, scientific thought is that the modulus of particles 
dictates the in vivo biodistribution and circulation time.  Red blood cells are 
extraordinarily flexible, able to deform as they circulate in vivo and pass through 
restrictions in vasculature that are smaller than their diameter.71  To investigate the effect 
of particle modulus, we fabricated hydrogel microparticles, with tunable elasticity, in the 
shape (biconcave disks) and size (6 µm) resembling red blood cells (Figure 1.6A).60  
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Macroscopic coupons of the hydrogels with varied amounts of crosslinker resulted in 
moduli that ranged from 64 to 8 kPa, including the modulus of red blood cells (26 kPa).  
In microfluidic models of vascular constrictions, the low crosslinked, soft microparticles 
readily navigated channels that were 3 µm wide and 50 µm long, while rigid 
microparticles clogged the channels (Figure 1.6). 
 
 
Figure 1.6  Deformable red blood cell mimics.  (A) Fluorescent image of hydrated 10% 
crosslinked particles.  Scale bar is 20 µm.  (B) Image sequence of 1% crosslinked 
particles deforming to pass through 3 µm × 3.5 µm channel (25 ms between frames).  (C) 
10% crosslinked particles stuck at entrance of channels in microfluidic device.  Scale bars 
are 30 µm.60 
 
A B 
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For in vivo studies, it was found that microparticles with low modulus bypassed in vivo 
filtration mechanisms in various organs, such as the lung, and were able to circulate for 
several days with a 30-fold increase in elimination half-life relative to their rigid 
counterparts.  While flexible microparticles were mostly sequestered into the spleen, rigid 
microparticles were largely accumulated in the lungs (Figure 1.7).60  This study 
demonstrates that the modulus of particles is an important design parameter that affects 
pharmacokinetics and biodistribution. 
 
 
Figure 1.7  Biodistribution of red blood cell mimics.  (A) Distribution of particles in 
various tissues 2 h after dosing.  (B) Lung tissue of a mouse dosed with 10% crosslinked 
particles (red).  Cell nuclei are stained purple and the cytoskeleton (F-actin) is stained 
green.  (C) Lung tissue of a mouse dosed with 1% crosslinked particles.  Scale bars are 
50 µm.60 
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1.2.3  Particle Surface Charge 
Studies have demonstrated that the surface charge of particles plays an important 
role in cellular internalization.49-54  So the effect of ζ-potential of PRINT particles on 
cellular uptake was explored.  Cylindrical hydrogel PRINT nanoparticles (d = 150 nm 
and h = 450 nm) were fabricated, and their cellular uptake was investigated in vitro with 
HeLa cells.58  Nanoparticles were reacted with acetic anhydride to passivate protonated 
surface amine groups, shifting the ζ-potential from +35 mV to -34 mV.  Positively 
charged nanoparticles internalized into 84% of cells after an incubation period of 1 h.  
However, less than 5% of cells internalized the negatively charged counterparts.  This 
suggests that the surface charge of particles is a critical factor in cellular internalization 
and the design of drug delivery agents. 
 
1.2.4  Particle Surface Chemistry 
Surface modification of particles is an extensively researched area, particularly 
with the aim of extending in vivo circulation and delivering therapeutics specifically to 
diseased cells.  Through the PRINT platform, we have fabricated nanoparticles to 
investigate the effect of multivalency on targeting and cell biology.63  The surface of 
cylindrical (d = 200 nm and h = 200 nm) hydrogel nanoparticles were conjugated with 
ligands specific for the transferrin receptor (TfR).  Human holo-transferrin-targeted 
nanoparticles (NP-hTf) and anti-TfR antibody-targeted nanoparticles (NP-OKT9) 
selectively internalized into HeLa, Ramos, H460, SKOV3, HepG2, and LNCaP cancer 
cell lines with varying levels of overexpression of the TfR, as well as HEK293 cells, a 
transformed normal human cell line with low expression of the TfR (Figure 1.8A).  
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Cellular uptake of targeted nanoparticles was found to correlate with the expression level 
of TfR in the cell lines, in addition to being dependent on nanoparticle concentration, 
targeting ligand density, and incubation times.  In contrast, control nanoparticles (NP-bTf 
and NP-IgG1) were minimally internalized (<10%) in all cell lines investigated.  When 
the viability of cells treated with nanoparticles was investigated, no cytotoxicity to 
targeted nanoparticles was observed for HeLa, H460, SKOV3, HepG2, or LNCaP cells.  
However, both NP-hTf and NP-OKT9 exhibited dose dependent cytotoxicity to Ramos 
Burkitt’s lymphoma cells (Figure 1.8B).  It is believed that this cytotoxicity is due to the 
multivalent nature of the nanoparticles with numerous copies of specific TfR ligands hTf 
and OKT9.  By functionalizing the surface of nanoparticles with specific targeting 
ligands, selective internalization was achieved, demonstrating the potential of targeted 
PRINT nanoparticles as site-specific drug nanocarriers.  Moreover, the cytotoxicity of 
NP-hTf and NP-OKT9 to Ramos cells only suggests the potential of targeted 
nanoparticles as effective therapeutics without an additional chemotherapeutic payload. 
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Figure 1.8  Transferrin receptor-targeted delivery of nanoparticles.  (A) Cellular uptake 
and (B) cytotoxicity of nanoparticles in various cancer cell lines.  ***, P < 0.001.63 
 
1.2.5  Delivery of Therapeutics 
Effective drug delivery systems are biocompatible, target specific, and can deliver 
and release a therapeutic payload at the tumor site.  One such system includes poly(lactic 
acid-co-glycolic acid) (PLGA) PRINT particles with high loading of docetaxel, up to 
40%.57  We demonstrated the facile fabrication of particles, in various shapes and sizes, 
from PLGA, a biocompatible and bioabsorbable polymer that has proven promise in 
biomedical devices and applications.72,73  Docetaxel was easily and efficiently 
encapsulated into PLGA cylindrical (d = 200 nm and h = 200 nm) nanoparticles.  When 
investigated in vitro with SKOV3 cells, nanoparticles loaded with 40% of docetaxel were 
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more efficacious (IC50 = 0.013 nM) than nanoparticles of lower loadings (10%, 20%, and 
30%), as well as Taxotere, the clinical formulation of docetaxel (IC50 = 0.103 nM, Table 
1.1 and Figure 1.9).  This suggests that docetaxel is released from the nanoparticles and 
can be delivered intracellularly to trigger cytotoxic effects that are more potent than the 
current therapy. 
 
Table 1.1  IC50 values of docetaxel-loaded PLGA PRINT nanoparticles and Taxotere.57 
 
IC50 (nM of Docetaxel) 
Taxotere 0.103 
10% Docetaxel Nanoparticles 0.379 
20% Docetaxel Nanoparticles 0.158 
30% Docetaxel Nanoparticles 0.072 
40% Docetaxel Nanoparticles 0.013 
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Figure 1.9  Cytotoxicity of Taxotere (red) and PLGA PRINT nanoparticles with 0% 
docetacel (black), 10% docetaxel (purple), 20% docetaxel (green), 30% docetaxel (dark 
blue), and 40% docetaxel (light blue) to SKOV3 cells after 72 h.  Blank nanoparticles 
(0% docetaxel) were dosed at equal nanoparticle concentrations to 10% docetaxel 
nanoparticles.57 
 
To minimize release of chemotherapeutics from nanocarriers until the drug 
delivery agents reach cancerous cells, particles are often engineered to be responsive to 
acidic and reducing environments within cells.  We investigated the delivery of the 
encapsulated doxorubicin in microparticles designed to release cargo under intracellular 
reducing environments such as the cytosol.65  Cubic (2 µm) hydrogel particles were 
fabricated with and without the reductively labile disulfide crosslinker N,N’-
cystaminebisacrylamide (Table 1.2).  Particles with the disulfide crosslinker released 
doxorubicin when incubated with the reductant dithiothreitol (DTT), but when stirred 
only in phosphate buffered saline (PBS), doxorubicin was not released from the 
microparticles.  For particles without the disulfide crosslinker, no release of doxorubicin 
was observed in the presence of DTT. 
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Table 1.2  Composition of reductively labile PRINT microparticles.  Adapted from [65]. 
Composition A B C 
Trimethylolpropane ethyoxylate (14/3 
EO/OH) triacrylate 57 87 57 
N,N’-Cystaminebisacrylamide 30 0 30 
Doxorubicin HCl 2 2 0 
2-Aminoethylmethacrylate HCl 10 10 10 
1-Hydroxycyclohexyl phenyl ketone 1 1 1 
 
When cytotoxicity of the particles was investigated in vitro in HeLa cells, particles 
containing the disulfide crosslinker and doxorubicin were markedly more cytotoxic (only 
10% viable cells) than those without the reductively labile disulfide crosslinker and were 
also nearly as potent as free doxorubicin (Figure 1.10).  This work suggests that the 
reducing intracellular environment triggered release of doxorubicin from the 
microparticles.  It is believed that the reduction of the disulfide crosslinker decreased the 
mesh density of the particles, thereby increasing the porosity of the particles for passive 
diffusion of the cargo. 
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Figure 1.10  Cytotoxicity of doxorubicin (dox) and doxorubicin-loaded PRINT 
microparticles to HeLa cells.  Dosing of 1-3 was 2.5, 160, 640 µg/mL for particles and 
0.05, 3.2, and 12.8 µg/mL for doxorubicin.65 
 
Along the same lines, stimuli responsive microparticles, composed of acid 
sensitive bifunctional silyl ether crosslinkers, were fabricated.61  A collection of novel 
crosslinkers based upon silyl ether chemistry was designed and synthesized: dimethyl 
(DMS), diethyl (DES), diisopropyl (DIS), and di-tert-butyl (DTS) silyl ether crosslinkers.  
Silyl ethers are acid labile, and their sensitivity is tunable.74  Large, bulky substituents on 
the silicon atom create more stable materials, whereas small substituents on the silicon 
atom produce molecules that are more sensitive to acid.  When 5 µm cubic microparticles, 
fabricated from these bifunctional silyl ether crosslinkers, were incubated under 
conditions to mimic lysosomal, endosomal, and physiological pH (pH 5.0, 6.0, and 7.4, 
respectively),75 all microparticles preferentially degraded under acidic conditions 
whereby the rate of degradation was accelerated at lower pH (Figure 1.11).  The rate of 
acid catalyzed hydrolysis was also varied amongst the particles fabricated from the 
various silyl ether crosslinkers.  Particles fabricated from the DMS crosslinker degraded 
most rapidly, on the order of hours, while particles fabricated from the DES crosslinker 
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were 13.6 times more stable, degrading over days.  Particles fabricated from the DIS 
crosslinker were most stable with a degradation half-life of 30.7 days, fully degrading 
over months.  This demonstrates the acid sensitivity of these bifunctional silyl ether 
crosslinkers as well as their tunability.  Silyl ether crosslinkers are a promising material 
in the delivery of therapeutic drugs in a controlled manner. 
 
 
Figure 1.11  Release of rhodamine-B from PRINT microparticles, fabricated from (A) 
DMS, (B) DES, and (C) DIS crosslinkers, at various pHs.61 
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 CHAPTER 2 
TARGETING PRINT® NANOPARTICLES FOR ENGINEERED DRUG DELIVERY 
CARRIERS 
 
2.1  Targeting Nanoparticles for Cancer Therapeutics 
One method of improving nanoparticles for therapeutic delivery systems is 
targeting.  The goal of targeting is to specifically deliver therapeutics to the disease site 
so as to improve both the bioavailability and the efficacy of the drug, while minimizing 
adverse systemic effects.  Delivery of the drug to the desired tissue is primarily achieved 
by two approaches: passive and active targeting.1-3 
 
2.1.1  Passive Targeting 
Passive targeting exploits the leaky vasculature and poor lymphatic drainage of 
the tumor microenvironment.  It is based upon the enhanced permeability and retention 
(EPR) effect.  The EPR effect describes the accumulation of particles and payload in the 
tumor as a result of highly permeable vasculature and defective lymphatic drainage 
(Figure 2.1).4  Through this method, the concentration of macromolecules in tumor tissue 
can reach levels up to 100 times higher than in normal tissue.3  Extravasation of particles 
into the tumor and subsequent release of drug from the carrier are essential to passive 
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targeting.  The extent of nanoparticle deposition and drug accumulation is dependent 
upon the size of the fenestrations and pathways in the tumor.  Liposomes have shown that 
the threshold for extravasation into tumors is around 400 nm.5  
Through passive targeting, therapeutic nanoparticle formulations have 
demonstrated improved efficacy over small molecule chemotherapeutics and become the 
basis for clinical therapy.6  One such success is Doxil, composed of doxorubicin 
encapsulated within liposomes that are coated with poly(ethylene glycol) (PEG).  It is 
approved for use in treating refractory Kaposi’s sarcoma, breast, and ovarian cancer and 
has been shown to be more effective than free doxorubicin.7  Formulation of the drug 
within liposomes reduced uptake by the reticuloendothetial system and extended 
circulation, thereby promoting tumor accumulation.8  Such advancements have prompted 
extensive research into passively targeting drug nanocarriers.  
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Figure 2.1  Model of the two approaches of nanoparticle targeting: passive and active 
(inset).  Adapted from [1]. 
 
2.1.2  Active Targeting 
Active targeting is an approach that involves the conjugation of specific ligands to 
the surface of nanoparticles.  These ligands recognize and bind specifically to tumor 
tissue through cellular surface receptors.  To achieve target specificity, the biomarker is 
uniquely expressed on the tumor cells with minimal expression on normal cells.9  Some 
receptors that have been investigated include the folate receptor, transferrin receptor, and 
human epidermal growth factor receptors.10  Through the ligand-receptor interactions, 
nanoparticles can internalize into target cells where the cargo can be released so as to 
minimize toxicity to adjacent healthy tissue. 
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A variety of ligands have been explored as targeting molecules for cancerous cells.  
Most prominent are antibodies, their fragments, and derivatives.  Within the last couple 
decades, antibody therapeutics have emerged as potential targeting agents in cancer 
therapy.  Numerous monoclonal antibodies (mAb) have been approved by the US Food 
and Drug Administration (FDA), including rituximab, trastuzumab, cetuximab, and 
bevacizumab.11  Despite clinical success as monotherapies, many antibody therapeutics 
are being investigated as adjuvant therapies in combination with chemotherapeutic drugs.  
As adjuvant therapies, improved effects are observed over treatment by antibody or 
chemotherapeutic alone.12-15  Thus, nanoparticles encapsulated with a high drug loading 
and targeted with specific antibodies may prove to be an advanced, more potent cancer 
therapy than either chemotherapy- or antibody-based treatments. 
An advantage of targeting with whole monoclonal antibodies is the divalent 
nature present on a single antibody that allows for higher binding avidity.  Whole 
antibodies are also stable during long-term storage.  Furthermore, when immune cells 
bind to the Fc portion of antibodies on target cells, a signaling cascade is triggered to kill 
cancer cells.  Conversely, the Fc domain of antibodies can bind to receptors on normal 
cells and result in immunogenicity and uptake of nanoparticles in the liver and spleen.  
Thus, antibody-based targeting efforts also include antibody fragments such as antigen-
binding fragments (Fab), dimers of antigen-binding fragments (F(ab’)2), and single-chain 
fragment variables (scFv), seen in Figure 2.2.  Despite their safer systemic profiles due to 
diminished nonspecific binding, antibody and engineered fragments are less stable than 
their whole counterparts.16,17 
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Figure 2.2  Various targeting ligands based upon antibodies.  Adapted from [1]. 
  
Aptamers, nucleic acid-based ligands, have also been explored as targeting agents 
for nanoparticles.18  They are DNA or RNA oligonucleotides that fold by intramolecular 
interaction into conformations that have binding properties.  They can be developed to 
bind antigens with high affinity and specificity.19  They can also be selected to bind to 
various targets such as transmembrane and intracellular proteins, carbohydrates, and 
small molecules.20  Thus, aptamers have been investigated as targeting agents and have 
demonstrated potential to improve nanoparticulate drug carrier systems.  For instance, 
nanoparticles encapsulated with chemotherapeutics have demonstrated increased efficacy 
in vivo as a result of aptamers targeting prostate cancer cells.21,22 
Peptides have also demonstrated potential as targeting agents.  Through 
combinatorial libraries, short peptides of 10-15 amino acids have been developed to bind 
specifically to proteins and cells.23,24  They are attractive alternatives to antibodies 
because of their small size, increased stability, lower immunogenicity, and ease of 
manufacturing.  One of the most widely studied peptides is the RGD (arginine-glycine-
aspartic acid) peptide, which binds to the αvβ3 cell adhesion integrin on endothelial cells.  
It has been shown to enhance intracellular accumulation of nanoparticles in 
neuroblastoma and breast cancer models in vivo.25-27  Cilengitide is a cyclic RGD peptide 
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that is being studied in clinical trials for the treatment of glioblastoma, pancreatic, and 
non-small cell lung cancer.28-30  Despite the promise of the RGD peptide, it is nonspecific 
and binds to other integrins, including α5β1 and α4β1, so it is not specific to cancer cells 
and can also target healthy tissue.1 
Utilizing nanoparticles to target receptors associated with metabolic rates has 
been extensively researched.  As cancer cells grow rapidly, receptors including the 
epidermal growth factor receptor (EGFR),31 folate receptor (FR),32 and transferrin 
receptor (TfR)33 are commonly overexpressed.  Specific protein ligands for these 
receptors have been conjugated onto nanoparticles to achieve specific targeting in 
diseased cells.  Nanoparticles targeted with epidermal growth factor34,35 or transferrin36,37 
have demonstrated increased delivery in cancer cells for improved therapeutic efficacy.  
Similarly, folic acid has been employed as a targeting agent for the FR, and nanoparticles 
targeted with the small molecule have shown greater intracellular accumulation and 
enhanced therapeutic potency.38-40 
 
2.2  Nanoparticles Targeting the Folate Receptor  
 
2.2.1  Introduction 
The folate receptor (FR) is a cellular membrane glycoprotein with limited 
expression on healthy tissue but amplified expression on cancer cells, such as ovarian, 
breast, lung, and prostate cancers.41-43  Expression of the FR has been correlated with the 
stage or grade of the cancer.  Metastatic cancers generally express significantly more FR 
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than localized tumors, and high overexpression of the FR is associated with poor 
prognosis.44,45  Although generally absent from most normal tissues, the FR is found at 
significant levels in the choroid plexus, placenta, lung, intestine, and kidney.  However, 
these receptors are largely inaccessible to plasma folates.46  Consequently, the FR is an 
attractive biomarker for targeted nanotherapeutics because of its prevalence amongst a 
variety of cancer cells but limited expression on normal cells. 
Two general strategies for targeting the FR involve folic acid or monoclonal 
antibodies.  Folic acid is a small molecule (MW 441) with high affinity for the FR (Kd 
~0.1 nM) because it is necessary for the synthesis of nucleotide bases.  Thus, it plays a 
critical role in cellular survival and proliferation.47,48  Folic acid is an attractive targeting 
ligand because of its low molecular weight, solubility, stability, lack of immunogenicity, 
commercial availability, and facile conjugation to nanocarriers.49  Consequently, 
nanoparticles conjugated with folic acid as a targeting ligand have been widely 
researched and have demonstrated selective intracellular uptake in diseased cells for 
delivery of therapeutics.39,50,51  Similarly, monoclonal antibodies against the FR (i.e., 
MOv18, MOv19) have also been explored as targeting ligands for drug and diagnostic 
nanocarriers.42  Through either targeting ligand, nanoparticles targeting the FR bind to 
cancer cells and are delivered intracellularly through receptor-mediated endocytosis. 
 
2.2.2  Experimental 
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2.2.2.1  Chemicals and Reagents 
Biotinylated isotype control mouse IgG was purchased from eBioscience.  Anti-
folate receptor (FR) monoclonal antibody (mAb; MOv18) was purchased from Axxora.  
UltraAvidin was purchased from Leinco Technologies.  Biotin-poly(ethylene glycol)-
succinimidyl carboxymethyl ester (941 g/mol; NHS-PEG12-biotin) was purchased from 
Thermo Scientific.  Biotin-poly(ethylene glycol)-succinimidyl carboxymethyl ester (3400 
g/mol for PEG; NHS-PEG3400-biotin) was purchased from Laysan Bio.  Anhydrous 
dimethylformamide (DMF) and pyridine were purchased from Acros.  Acetic anhydride 
was purchased from Fisher Scientific.  All other reagents were purchased from Sigma 
Aldrich. 
 
2.2.2.2  Cells and Culture 
SKOV3, MCF7, OVCAR3, and HeLa, cells were from UNC LCCC Tissue 
Culture Facility.  SKOV3 cells were maintained in McCoy’s 5A with 10% FBS.  
OVCAR3 cells were maintained in RPMI 1640 with 10% FBS.  MCF7 and HeLa cells 
were maintained in MEM with 10% FBS.  All media and supplements were from Gibco 
except McCoy’s 5A, which was from Mediatech. 
 
2.2.2.3  Fabrication of PRINT Nanoparticles 
Cylindrical nanoparticles (d = 200 nm and h = 200 nm) were fabricated using the 
PRINT technique.  Nanoparticles were prepared from a starting monomer solution (5% 
wt/vol in DMF) consisting of 87 wt % of trimethyloylpropane ethoxylate triacrylate (MW 
= 428 g/mol; PEG428 triacrylate), 10 wt % of 2-aminoethyl methacrylate hydrochloride, 2 
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wt % of fluorescein o-acrylate, and 1 wt % of 2,2-diethoxyacetophenone.  A monomer 
film was cast upon a sheet of poly(ethylene terephthalate) (PET) by spreading 90 µL of 
monomer solution with a mayer rod (#2, R.D. Specialties), and it was dried with heat 
using a heat gun to remove the solvent DMF.  The monomer film and patterned mold, 
provided by Liquidia Technologies, were laminated together under pressure (40 PSI) and 
then delaminated, by gently splitting the mold and PET, to yield a mold with filled 
cavities.  The filled mold was laminated with a fresh sheet of PET and then exposed to 
UV irradiation (λ = 365 nm, power 90 mW/cm2) for 4 min under a nitrogen purge.  The 
mold was removed, leaving nanoparticles transferred on the sheet of PET.  This was due 
to the higher surface energy of the PET.  Milli-Q filtered water (400 µL) was placed on 
the PET, and nanoparticles were collected mechanically with a cell scraper.  The 
harvested particles were washed twice with water by centrifugation. 
 
2.2.2.4  Labeling anti-FR mAb with Biotin 
Anti-FR mAb (1 mL, 0.5 mg/mL in PBS) was reacted with NHS-PEG12-biotin 
(2.5 µL, 25 mg/mL in DMF) for 30 min at RT.  The reaction solution was then dialyzed 
in a Slide-A-Lyzer dialysis cassette (10k molecule weight cut-off; Thermo Scientific) 
against cold DPBS for 24 h at 4 °C to remove excess NHS-PEG12-biotin.  The 
biotinylated antibody was then collected and stored at 4 °C. 
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2.2.2.5  Determining the Biological Activity of Biotinylated anti-FR mAb 
MCF7 cells were trypsinized and seeded at 50,000 cells in 50 µL of DPBS per 
well in a round-bottom 96-well plate.  The primary antibody (anti-FR mAb, biotinylated 
anti-FR mAb, or IgG), at 0.5 mg/mL, was diluted 1:50 in DPBS, and 50 µL of the 
primary antibody was added to the cells and incubated for 30 min at 4 °C.  Cells were 
washed twice with cold DPBS by centrifugation.  The secondary antibody Alexa Fluor 
488 goat anti-mouse IgG (Invitrogen), at 2 mg/mL, was diluted 1:400 in DPBS.  The 
diluted secondary antibody (100 µL/well) was then incubated with the cells for 30 min at 
4 °C.  Subsequently, cells were washed twice with cold DPBS by centrifugation.  
Samples were resuspended in DPBS and analyzed using a Dako CyAn flow cytometer. 
 
2.2.2.6  Conjugation of anti-FR mAb/IgG to PRINT Nanoparticles 
Nanoparticles were conjugated with anti-FR mAb or IgG through a biotin-avidin 
linkage.  Nanoparticles in anhydrous DMF (500 µL at 2 mg/mL) were reacted with 5 mg 
of NHS-PEG3400-biotin in the presence of 10 µL anhydrous of pyridine; the nanoparticle 
dispersion was shaken on a vortex for 2 h.  Acetic anhydride (10 µL) was added to the 
dispersion, which was shaken for 10 min, to quench unreacted amines on the nanoparticle 
surface.  The nanoparticles were washed twice with Dulbecco’s phosphate buffered saline 
(DPBS) by centrifugation.  UltraAvidin (50 µL, 10 mg/mL) was added to the 
nanoparticles in DPBS (2 mg/mL).  The dispersion was shaken for 1 h.  The 
nanoparticles were washed twice with DPBS by centrifugation.  To target the 
nanoparticles, 50 µg of anti-FR mAb or IgG was added to the nanoparticle dispersion and 
was shaken for 30 min at room temperature and then kept overnight at 4 °C.  The 
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nanoparticles were washed twice with DPBS by centrifugation and then resuspended in 
DPBS. 
 
2.2.2.7  Physical Characterization of Nanoparticles 
Scanning electron microscopy samples were prepared by pipetting 10 µL of 
nanoparticle solution onto a glass slide.  Samples were dried and coated with 2 nm of 
gold palladium with a Cressington 108 auto sputter coater (Cressington Scientific 
Instruments).  Samples were imaged with a scanning electron microscope (Hitachi S-
4700).  The size (dynamic light scattering, DLS) and charge (ζ-potential) of the 
nanoparticles were determined for 20 µg/mL nanoparticle samples in a 1 mM potassium 
chloride solution with a Malvern Instruments Nano ZS. 
 
2.2.2.8  Determining the FR Expression in Cells 
HeLa, SKOV3, MCF7, and OVCAR3 cells were analyzed for expression of the 
FR following the same protocol described above for the determination of the biological 
activity of biotinylated anti-FR mAb. 
 
2.2.2.9  Quantitative In Vitro Cellular Targeting 
SKOV3 and HeLa cells were plated at 50,000 cells/well in a 24-well plate and 
allowed to adhere overnight at 37 °C and 5% CO2.  Nanoparticles in OPTI-MEM were 
incubated with cells at 37 °C and 5% CO2 for specified amounts of time and then 
removed.  The cells were washed twice with DPBS, trypsinized, and prepared for 
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analysis by flow cytometry with a 0.2% trypan blue solution containing 10% FBS in 
DPBS.  Samples were analyzed with a Dako CyAn flow cytometer. 
 
2.2.2.10  Inhibition of Cellular Internalization of Nanoparticles 
SKOV3 cells were plated at 50,000 cells/well in a 24-well plate and allowed to 
adhere overnight at 37 °C and 5% CO2.  Free anti-FR mAb or IgG, in varying amounts in 
OPTI-MEM, was dosed onto cells.  The cells were incubated at 37 °C for 1 h, after which 
free targeting ligands were removed.  Nanoparticles in OPTI-MEM, at 5 µg/mL, were 
incubated with cells at 37 °C for 4 h and then removed.  The cells were washed twice 
with DPBS, trypsinized, and prepared for analysis by flow cytometry with a 0.2% trypan 
blue solution containing 10% FBS in DPBS.  Samples were analyzed with a Dako CyAn 
flow cytometer. 
 
2.2.2.11  Confocal Microscopy 
SKOV3 cells (50,000) were seeded in T-25 flasks and allowed to adhere 
overnight at 37 °C and 5% CO2.  Cells were incubated with 15 µg/mL of nanoparticles in 
OPTI-MEM for 4 h at 37 °C.  Cells were washed by detachment with trypsin, 
resuspended in complete media, replated onto 35-mm2 glass bottom dishes with 1.5G 
cover slips (MatTek Corp.), and allowed to adhere overnight at 37 °C.  Nuclei were 
stained with 2.5 µM DRAQ5 (Biostatus Ltd.).  Cells were fixed with 4% 
paraformaldehyde.  Cells were imaged with a confocal laser scanning microscope 
(Olympus Fluoview FV500). 
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2.2.3  Results and Discussion 
 
2.2.3.1  Nanoparticle Fabrication and Conjugation with Anti-FR Antibodies 
The PRINT technology is a versatile platform for the fabrication of particles 
because it affords precise control over particle size, shape, composition, and surface 
chemistry.52-60  Through this technique, cylindrical nanoparticles (d = 200 nm and h = 
200 nm), primarily composed of poly(ethylene glycol) (PEG; 428 g/mol) triacrylate were 
fabricated (Figure 2.3). 
 
 
Figure 2.3  SEM of 200 nm cylindrical PRINT nanoparticles.  Scale bar is 3 µm. 
 
Also included within the nanoparticles were 2-aminoethyl methacrylate hydrochloride, 
fluorescein o-acrylate, and 2,2-diethoxyacetophenone (Table 2.1).  The 2-aminoethyl 
methacrylate hydrochloride provided amine functionalities for nanoparticle surface 
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modification, while fluorescein o-acrylate fluorescently labeled the nanoparticles to be 
tracked and visualized in vitro. 
 
Table 2.1  Composition of PEG-based PRINT nanoparticles for targeting with anti-FR 
antibodies. 
Monomers Wt % 
PEG428 triacrylate 87 
2-Aminoethyl methacrylate hydrochloride 10 
Fluorescein o-acrylate 2 
2,2-Diethoxyacetophenone 1 
 
Pre-functionalized nanoparticles with no surface modifications had a hydrodynamic 
diameter of 297 nm with a narrow polydispersity index of 0.039.  They were cationic and 
possessed a positive ζ-potential of +29.2 ± 0.6 mV because of the amine functional 
groups at the surface of the nanoparticles (Table 2.2). 
 
Table 2.2  Hydrodynamic diameters and zeta potentials of 200 nm cylindrical PRINT 
nanoparticles. 
Nanoparticle Diameter (nm) PDI ζ-Potential (mV) 
Pre-functionalized 297 0.039 +29.2 ± 0.6 
Biotinylated 300 0.010 -20.6 ± 0.5 
NP-FR 298 0.08 -23.1 ± 0.8 
NP-IgG 298 0.07 -26.6 ± 1.4 
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Previously demonstrated, positively charged particles can internalize into cells quickly 
albeit nonspecifically53,61,62 and can also induce cytotoxicity.63  Thus, such particles are 
not ideal as drug delivery systems.  However, negatively charged particles can 
circumvent these issues because they exhibit decreased cellular uptake.53,61,62  Therefore, 
conjugating targeting ligands to negatively charged particles can achieve specific cellular 
internalization that is better suited for improved drug delivery agents.59 
For this reason, the surface of PRINT nanoparticles were functionalized and 
targeted with anti-human folate receptor (FR) monoclonal antibodies (mAb; Figure 2.4).  
Cationic pre-functionalized nanoparticles were initially reacted with NHS-PEG3400-biotin.  
This was followed by acetic anhydride to quench any unreacted amines, thereby shifting 
the ζ-potential to negative (-20.6 mV for biotinylated nanoparticles, Table 2.2) so that 
nonspecific cellular internalization could be avoided.  Targeted antibodies were 
conjugated to the nanoparticles through biotin-avidin linkages, so avidin was first reacted 
with biotinylated nanoparticles, followed by the targeting ligands, anti-FR antibody and 
IgG.  Nanoparticles functionalized with the anti-FR antibodies (NP-FR) were designed to 
specifically target cancer cells that overexpress the FR, while nanoparticles targeted with 
IgG (NP-IgG) were tailored as control nanoparticles.  Targeted nanoparticles maintained 
hydrodynamic diameters around 300 nm and negative ζ-potentials of about -25 mV so 
that nonspecific cellular internalization and cytotoxicity could be avoided. 
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Figure 2.4  Scheme of nanoparticle surface modification for targeting with antibodies. 
 
As the anti-FR antibody was attached onto nanoparticles through biotin-avidin 
linkages, the antibody was first modified with biotin to enable conjugation.  The antibody 
was reacted with NHS-PEG12-biotin, which randomly labeled the antibody with biotin.  
Because biotinylation of the antibody was indiscriminate, biological activity of the 
antibody was investigated by flow cytometry before conjugation to nanoparticles.  
Binding of the original antibody and the biotinylated antibody to the FR on MCF7 
(human breast cancer) cells was studied using a secondary antibody labeled with the 
fluorescent dye Alexa Fluor 488.  Histograms in Figure 2.5 illustrate similar shifts in 
fluorescence for both the unmodified antibody and the biotinylated antibody.  This 
demonstrates that the biotinylated antibody maintained its biological function.  Labeling 
the anti-FR antibody with biotin did not disrupt the binding of the antibody to the FR, so 
the biotinylated antibodies were utilized in targeting PRINT nanoparticles. 
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Figure 2.5  Flow cytometry histograms of (A) MCF7 cells, (B) anti-FR mAb binding, (C) 
no nonspecific binding of the fluorescent secondary Ab, and (D) binding of biotinylated 
anti-FR mAb. 
 
2.2.3.2  Determination of FR-Positive Cell Lines 
Before investigating cellular internalization of the nanoparticles, a variety of cell 
lines were investigated for the expression of the FR to determine appropriate in vitro 
models.  HeLa (human cervical cancer), MCF7 (human breast adenocarcinoma), and 
SKOV3 and OVCAR3 (human ovarian adenocarcinoma) cells were probed for the 
expression of the FR.  Cells were stained for the FR with anti-FR mAb and a secondary 
antibody labeled with the fluorescent Alexa Fluor 488 dye and then analyzed by flow 
cytometry.  SKOV3, MCF7, and OVCAR3 cells exhibited amplified expression of the 
FR, while HeLa cells had minimal levels (Figure 2.6).  Based on these results, SKOV3 
cells were chosen as a FR-positive cell line for in vitro studies, and HeLa cells were 
selected as a FR-negative cell line. 
A B 
C D 
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Figure 2.6  Histograms illustrating the level of expression of the FR in HeLa, SKOV3, 
MCF7, and OVCAR3 cells. 
 
2.2.3.3  Quantitative In Vitro Cellular Uptake 
Cellular internalization of the nanoparticles was investigated in SKOV3 and HeLa 
cells.  SKOV3 cells overexpress the FR, but HeLa cells have negligible levels of the 
receptor.  Initially, pre-functionalized nanoparticles were studied.  Nanoparticles were 
incubated at 37 °C with the cells at varied nanoparticle concentrations and incubation 
times (2 and 4 h).  Uptake of pre-functionalized nanoparticles was analyzed by a flow 
Cells only 
Anti-FR 
mAb + 2° 
Ab-AF488 
IgG isotype 
+ 2° Ab-
AF488 
HeLa SKOV3 MCF7 OVCAR3 
2° Ab-AF488 
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cytometry technique to quantify the percentage of cells with internalized nanoparticles.64  
In both SKOV3 and HeLa cells, pre-functionalized nanoparticles were rapidly 
internalized in a dose dependent fashion (Figure 2.7).  There was a high amount of 
nanoparticle internalization, over 95% in HeLa cells and over 85% in SKOV3 cells at 4 h.  
In 2 h, there was only a slight decrease in uptake with 94% of HeLa cells and 75% of 
SKOV3 cells with internalized nanoparticles.  Rapid internalization of pre-functionalized 
nanoparticles in both cell lines was due to the positive ζ-potential that induces 
nonspecific cellular binding and uptake.  Rapid, nonspecific internalization of positively 
charged PRINT particles has also been demonstrated previously.53,65 
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Figure 2.7  Internalization of pre-functionalized nanoparticles in SKOV3 and HeLa cells 
as a function of nanoparticle concentration and incubation time. 
 
Positively charged particles can internalize into cells nonspecifically53,61,62 and 
potentially induce cytotoxicity.63  To avoid these issues, targeting ligands are often 
conjugated to the surface of nanoparticles to promote specific intracellular accumulation.  
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Thus, pre-functionalized nanoparticles were functionalized for a negative ζ-potential to 
evade nonspecific cellular uptake and then conjugated with targeting ligands for the FR 
to support specific internalization.  Targeted nanoparticles NP-FR and NP-IgG were 
incubated with SKOV3 cells at varied nanoparticle concentrations and incubation times.  
In SKOV3 cells, which overexpress the FR, NP-FR was selectively internalized into cells, 
in a dose and time dependent manner, to over 70% at 4 h and over 55% in 2 h, while 
minimal cells (<14%) internalized NP-IgG (Figure 2.8).  Low uptake of NP-IgG was 
attributed to the negative charge of the nanoparticles as well as the nonspecific IgG 
ligands.  In contrast, despite the negative ζ-potential, NP-FR exhibited higher uptake due 
to the specific binding of the anti-FR mAb to the FR, which induced receptor-mediated 
endocytosis of the nanoparticles.  By conjugating a targeting ligand to the surface of the 
nanoparticles, NP-FR were able to overcome the low uptake of negatively charged 
particles to specifically internalize into FR-expressing SKOV3 cells. 
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Figure 2.8  Internalization of anti-FR mAb-targeted nanoparticles into SKOV3 cells as a 
function of nanoparticle concentration and incubation time. 
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Additionally, NP-FR and NP-IgG were incubated with HeLa cells, which have 
minimal expression of the FR.  Uptake of targeted nanoparticles was low as compared to 
that in SKOV3 cells (Figure 2.9).  There was also an insignificant difference between 
NP-FR and NP-IgG, attributed to the low level of the FR in HeLa cells.  As observed 
between SKOV3 and HeLa cells, the level of the FR in the cell lines strongly influences 
the specific uptake of NP-FR.  The amount of internalization of NP-FR correlates well to 
the expression level of the FR on the cell lines. 
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Figure 2.9  Internalization of anti-FR mAb-targeted nanoparticles in HeLa cells as a 
function of nanoparticle concentration and incubation time. 
 
2.2.3.4  Inhibition of Nanoparticle Cellular Targeting 
Specific targeting and uptake of NP-FR was confirmed in SKOV3 cells through 
competition with free anti-FR mAb.  SKOV3 cells were incubated with free anti-FR mAb 
prior to addition of NP-FR to allow the cellular FR to be bound by free ligands and thus, 
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decrease those available for binding with targeted nanoparticles.  As seen in Figure 2.10, 
SKOV3 cells preincubated with free anti-FR mAb internalized less NP-FR, with only 
37% of cells having internalized nanoparticles.  Addition of the nonspecific IgG control 
antibody to SKOV3 cells prior to incubation with NP-FR did not influence the binding 
and internalization of the targeted nanoparticles.  Specific targeting and inhibition of 
uptake with only free anti-FR mAb indicate that NP-FR selectively bind to the FR and 
internalize through receptor-mediated endocytosis. 
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Figure 2.10  Inhibition of internalization of anti-FR mAb-targeted nanoparticles with free 
ligand in SKOV3 cells. 
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2.2.3.5  Confocal Microscopy 
Targeting and internalization of NP-FR in SKOV3 cells was also visualized by 
confocal microscopy.  Cells were incubated with fluorescein-labeled NP-FR.  As 
expected, targeted nanoparticles bound and internalized into SKOV3 cells (Figure 2.11).  
NP-FR specifically targeted the FR on the surface of the cells, and through FR-mediated 
endocytosis, targeted nanoparticles were internalized into the cells.  Based on the data, 
PRINT nanoparticles targeted with anti-FR mAb are potential drug delivery vehicles that 
can selectively bind to cells that overexpress the FR and accumulate intracellularly for 
localized delivery of a therapeutic payload. 
 
Figure 2.11  Confocal microscopy images of specific targeting and internalization of NP-
FR in SKOV3 cells. 
   
2.2.3.6  Effect of Targeted Ligand Density on Nanoparticle Uptake 
To better understand the influence of multivalency on targeting, nanoparticles 
were fabricated with varying densities of anti-FR mAb (100% to 0%) by substituting the 
targeting ligand with the control ligand IgG during the process of conjugation to 
nanoparticles.  Nanoparticles were incubated with SKOV3 cells for 4 h at 37 °C, and 
SKOV3 cells were analyzed for nanoparticle uptake by flow cytometry.  As the density 
DIC NP-FR Nucleus Merge 
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of anti-FR mAb was decreased on the nanoparticles, internalization of the nanoparticles 
also began to decrease (Figure 2.12).  When the density of anti-FR mAb was lowered 
from 100% to 60%, uptake of NP-FR decreased slightly from 56% to 50%.  This may 
suggest that nanoparticles functionalized with 60% of the targeting ligand can achieve a 
nearly similar extent of nanoparticle internalization as those with 100% of anti-FR mAb.  
Therefore, other targeting or therapeutic ligands may be conjugated to nanoparticles, in 
addition to anti-FR mAb, to increase target specificity or therapeutic efficacy while 
maintaining high selective targeting of the nanoparticles to cancer cells.  However, when 
the density of anti-FR mAb was further decreased to 20%, a more prominent effect was 
observed with only 25% of SKOV3 cells having internalized nanoparticles.  At 10% of 
the targeting anti-FR mAb, effects from the nonspecific ligand IgG were more prevalent 
as uptake of these nanoparticles were nearly similar to those with 0% of the anti-FR mAb 
(or 100% of IgG).  In both cases, less than 7% of cells internalized nanoparticles.   
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Figure 2.12  Internalization of NP-FR with varied density of the anti-FR mAb targeting 
ligand in SKOV3 cells. 
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2.2.4  Conclusions 
PRINT nanoparticles were created and investigated for active targeting as 
possible drug delivery agents.  Cylindrical nanoparticles, composed primarily of 
biocompatible PEG, were successfully fabricated and converted from a positive surface 
charge to a negative ζ-potential to avoid nonspecific cellular uptake.  They were further 
engineered with anti-FR mAb targeting ligands on the surface to facilitate specific 
targeting and internalization into cancer cells with an amplified level of the FR.  When 
investigated in vitro by flow cytometry and confocal microscopy, NP-FR exhibited 
specific targeting and internalization into FR-expressing SKOV3 cells.  The targeted 
nanoparticles internalized in a dose and time dependent manner.  It was also shown that 
NP-FR internalized into SKOV3 cells through FR-mediated endocytosis, triggered by the 
binding of anti-FR mAb with the receptor, because internalization of NP-FR was 
inhibited by free targeting ligands.  Additionally, uptake of NP-FR correlated with the 
expression level of FR in cells.  SKOV3 cells readily internalized NP-FR, while the 
targeted nanoparticles did not heavily accumulate in HeLa cells.  Moreover, NP-FR, with 
a decreased density of targeting ligands on the nanoparticle surface, still internalized into 
SKOV3 cells, suggesting that nanoparticles with decreased multivalency can still target 
and accumulate in cancer cells.  In contrast to NP-FR, NP-IgG were minimally 
influenced by all these factors, exhibiting low cellular internalization, because of their 
negative surface charge and nonspecific surface ligands.  By utilizing the PRINT 
platform, biocompatible nanoparticles were fabricated and developed into potential drug 
nanocarriers that actively target FR-expressing cancer cells. 
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2.2.5  Future Work 
Conjugating antibodies to the surface of nanocarriers as a method to enhance 
specific targeting of the drug delivery system is commonly employed by researchers.  For 
the FR, targeting is primarily achieved with anti-FR mAb or folic acid, a small molecule 
ligand for the FR.42  Because of its small size, it can be easily manipulated for 
conjugation and may be nonimmunogenic as well.49  Thus, it is an appealing ligand for 
targeting the FR that has been researched by others.39,42,50,51  Cylindrical PRINT 
nanoparticles were fabricated and conjugated with folic acid and investigated in vitro 
with FR-expressing KB cells.  After 4 h at 37 °C, nanoparticles targeted with folic acid 
were internalized into 85% of cells, while just 26% of KB cells internalized untargeted 
nanoparticles (Figure 2.13). 
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Figure 2.13  Internalization of nanoparticles targeted with folic acid in KB cells. 
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While the results are promising, further studies are required to confirm targeting and 
internalization mechanisms of folic acid-targeted nanoparticles.  Additionally, future 
investigations with nanoparticles targeted with the small molecule folic acid compared to 
those targeted with anti-FR mAb would help to elucidate differences in nanoparticle 
targeting between the targeting ligands.  The PRINT platform is an ideal technique for 
such a study as nanoparticles can be readily fabricated and studied with independent 
control of the surface chemistry and targeting ligands.  These basic studies would benefit 
and advance efforts to develop improved targeted therapeutic nanocarriers. 
 
2.3  Nanoparticles Targeting the HER2 Receptor 
 
2.3.1  Introduction 
The human epidermal growth factor receptor 2 (HER2, HER2/neu, ErbB2) is a 
transmembrane tyrosine kinase receptor of the epidermal growth factor receptor (EGFR) 
family.66  It is minimally expressed in normal tissue but is overexpressed in ovarian, lung, 
and about 30% of breast cancers and is largely associated with poor prognosis.67-70  There 
are no known ligands for the HER2 receptor, but Herceptin (trastuzumab; Genentech) is a 
humanized monoclonal antibody approved for the treatment of metastatic breast cancer 
that binds the receptor with specificity.  Herceptin inhibits tumor growth as a 
monotherapy, but when administered in combination with cytotoxic agents, it acts 
synergistically.71,72  As such, Herceptin is an appealing targeting ligand for the delivery 
of nanoparticles containing chemotherapeutic drugs for a dual functional nanocarrier.  
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Thus, researchers have studied the targeting of nanoparticles with Herceptin and found 
that nanoparticles effectively and specifically target HER2-positive cancer cells and 
internalize through receptor-mediated endocytosis.73-76  When loaded with cytotoxic 
agents, such as paclitaxel, methotrexate, and doxorubicin, targeted nanoparticles still 
demonstrated specific targeting and internalization into cells and were generally more 
potent than the free drug.77-79 
Herein, we describe the fabrication and modification of PRINT nanoparticles with 
ligands specific for the HER2 receptor and the in vitro targeting properties of the 
nanoparticles.  We investigated nanoparticles that were conjugated with Herceptin 
through noncovalent biotin-avidin linkages.  Additionally, nanoparticles were covalently 
modified with an engineered heptameric ligand for the HER2 receptor.  These 
nanoparticles were studied for targeting and accumulation in various HER2-positive 
cancer cell lines.  Through these two ligands, we studied the implications of the 
multivalent nature of the nanoparticles on targeting to emphasize that such considerations 
are necessary in the rational design of targeted nanoparticles for cancer therapeutics. 
 
2.3.2  Experimental 
 
2.3.2.1  Chemicals and Reagents 
Control mouse IgG and biotinylated IgG were purchased from eBioscience.  
Herceptin (Genentech) was purchased from the UNC Hospitals.  The engineered 
heptameric ligand for the HER2 receptor was provided by Professor Rihe Liu (UNC 
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Eshelman School of Pharmacy).  UltraAvidin was purchased from Leinco Technologies.  
Biotin-poly(ethylene glycol)-succinimidyl carboxymethyl ester (3400 g/mol for PEG; 
NHS-PEG3400-biotin) and maleimide-poly(ethylene glycol)- succinimidyl carboxymethyl 
ester (5000 g/mol for PEG; NHS-PEG5000-Mal) were purchased from Laysan Bio.  
Biotin-poly(ethylene glycol)-succinimidyl carboxymethyl ester (941 g/mol; NHS-PEG12-
biotin) and borate buffer were purchased from Thermo Scientific.  Anhydrous 
dimethylformamide (DMF) and pyridine were purchased from Acros.  Acetic anhydride 
was purchased from Fisher Scientific.  All other reagents were purchased from Sigma 
Aldrich. 
 
2.3.2.2  Cells and Culture 
BT474, SKOV3, MCF7, OVCAR3, and HeLa cells were from UNC LCCC 
Tissue Culture Facility.  BT474 cells were maintained in RPMI 1640 with 10% FBS, 1.5 
g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, and 
0.02 mg/mL human insulin.  SKOV3 cells were maintained in McCoy’s 5A with 10% 
FBS.  OVCAR3 cells were maintained in RPMI 1640 with 10% FBS.  MCF7 and HeLa 
cells were maintained in MEM with 10% FBS.  All media and supplements were from 
Gibco except McCoy’s 5A, which was from Mediatech. 
 
2.3.2.3  Fabrication of PRINT Nanoparticles 
Cylindrical nanoparticles (d = 200 nm and h = 200 nm) were fabricated using the 
PRINT technique.  Nanoparticles were prepared from a starting monomer solution (5% 
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wt/vol in DMF) consisting of 77 wt % of PEG700 diacrylate, 20 wt % of 2-aminoethyl 
methacrylate hydrochloride, 2 wt % of fluorescein o-acrylate, and 1 wt % of 2,2-
diethoxyacetophenone.  A monomer film was cast upon a sheet of poly(ethylene 
terephthalate) (PET) by spreading 90 µL of monomer solution with a mayer rod (#2, R.D. 
Specialties), and it was dried with heat using a heat gun to remove the solvent DMF.  The 
monomer film and patterned mold, provided by Liquidia Technologies, were laminated 
together under pressure (40 PSI) and then delaminated, by gently splitting the mold and 
PET, to yield a mold with filled cavities.  The filled mold was laminated with a fresh 
sheet of PET and then exposed to UV irradiation (λ = 365 nm, power 90 mW/cm2) for 4 
min under a nitrogen purge.  The mold was removed, leaving nanoparticles transferred on 
the sheet of PET.  This was due to the higher surface energy of the PET.  Milli-Q filtered 
water (400 µL) was placed on the PET, and nanoparticles were collected mechanically 
with a cell scraper.  The harvested particles were washed twice with water by 
centrifugation. 
 
2.3.2.4  Labeling Herceptin with Biotin 
Herceptin (1 mL, 2 mg/mL in PBS) was reacted with NHS-PEG12-biotin (2.5 µL, 
25 mg/mL in DMF) for 30 min at RT.  The reaction solution was then dialyzed in a Slide-
A-Lyzer dialysis cassette (10k molecule weight cut-off; Thermo Scientific) against cold 
DPBS for 24 h at 4 °C to remove excess NHS-PEG12-biotin.  The biotinylated antibody 
was then collected and stored at 4 °C. 
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2.3.2.5  Determining the Biological Activity of Biotinylated Herceptin 
BT474 cells were trypsinized and seeded at 50,000 cells in 50 µL of DPBS per 
well in a round-bottom 96-well plate.  The primary antibody Herceptin or biotinylated 
Herceptin, at 2 mg/mL, was diluted 1:200 in DPBS, and IgG, at 0.5 mg/mL, was diluted 
1:50 in DPBS.  The diluted primary antibody (50 µL/well) was added to the cells and 
incubated for 30 min at 4 °C.  Cells were washed twice with cold DPBS by centrifugation.  
The secondary antibody Alexa Fluor 488 goat anti-human IgG or Alexa Fluor 488 goat 
anti-mouse IgG (Invitrogen), at 2 mg/mL, was diluted 1:400 in DPBS.  The diluted 
secondary antibody (100 µL/well) was then incubated with the cells for 30 min at 4 °C.  
Subsequently, cells were washed twice with cold DPBS by centrifugation.  Samples were 
resuspended in DPBS and analyzed using a BD LSRII flow cytometer with an HTS 
system. 
 
2.3.2.6  Noncovalent Conjugation of Herceptin/IgG to PRINT Nanoparticles 
Nanoparticles were conjugated with Herceptin or IgG through a biotin-avidin 
linkage.  Nanoparticles in anhydrous DMF (500 µL at 2 mg/mL) were reacted with 5 mg 
of NHS-PEG3400-biotin in the presence of 10 µL anhydrous of pyridine; the nanoparticle 
dispersion was shaken on a vortex for 2 h.  Acetic anhydride (10 µL) was added to the 
dispersion, which was shaken for 10 min, to quench unreacted amines on the nanoparticle 
surface.  The nanoparticles were washed twice with Dulbecco’s phosphate buffered saline 
(DPBS) by centrifugation.  UltraAvidin (50 µL, 10 mg/mL) was added to the 
nanoparticles in DPBS (2 mg/mL).  The dispersion was shaken for 1 h.  The 
nanoparticles were washed twice with DPBS by centrifugation.  To target the 
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nanoparticles, 50 µg of biotinylated Herceptin or IgG was added to the nanoparticle 
dispersion and was shaken for 30 min at room temperature and then kept overnight at 4 
°C.  The nanoparticles were washed twice with DPBS by centrifugation and then 
resuspended in DPBS. 
 
2.3.2.7  Covalent Conjugation of Herceptin/Heptamer/IgG to PRINT Nanoparticles 
Nanoparticles in anhydrous DMF (500 µL at 2 mg/mL) were reacted with 5 mg of 
NHS-PEG5000-maleimide in the presence of 10 µL anhydrous of pyridine; the 
nanoparticle dispersion was shaken on a vortex for 2 h.  Acetic anhydride (10 µL) was 
added to the dispersion, which was shaken for 10 min, to quench unreacted amines on the 
nanoparticle surface.  Nanoparticles were washed twice with Milli-Q filtered water by 
centrifugation.  To target nanoparticles with antibodies, 50 µg of Herceptin or IgG was 
added to the nanoparticle dispersion (500 µL at 2 mg/mL in 50 mM borate buffer pH 8.5).  
To target nanoparticles with the heptamer, 50 µg of the heptamer was added to the 
nanoparticle dispersion (500 µL at 2 mg/mL in DPBS pH 7.4).  All nanoparticle 
dispersions were shaken for 4 h at room temperature.  Nanoparticles were washed twice 
with DPBS by centrifugation and then resuspended in DPBS. 
 
2.3.2.8  Physical Characterization of Nanoparticles 
Scanning electron microscopy samples were prepared by pipetting 10 µL of 
nanoparticle solution onto a glass slide.  Samples were dried and coated with 2 nm of 
gold palladium with a Cressington 108 auto sputter coater (Cressington Scientific 
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Instruments).  Samples were imaged with a scanning electron microscope (Hitachi S-
4700).  The size (dynamic light scattering, DLS) and charge (ζ-potential) of the 
nanoparticles were determined for 20 µg/mL nanoparticle samples in a 1 mM potassium 
chloride solution with a Malvern Instruments Nano ZS. 
 
2.3.2.9  Determining the Expression of the HER2 Receptor in Cells 
BT474, SKOV3, MCF7, OVCAR3, and HeLa cells were analyzed for expression 
of the HER2 receptor following the same protocol described above for the determination 
of the biological activity of biotinylated Herceptin. 
 
2.3.2.10  Quantitative In Vitro Cellular Targeting 
BT474, SKOV3, and MCF7 cells were plated at 10,000 cells/well in a 96-well 
plate and allowed to adhere overnight at 37 °C and 5% CO2.  Nanoparticles in OPTI-
MEM were incubated with cells at 37 °C and 5% CO2 for specified amounts of time and 
then removed.  The cells were washed twice with DPBS, trypsinized, and prepared for 
analysis by flow cytometry with a 0.2% trypan blue solution containing 10% FBS in 
DPBS.  Samples were analyzed with a BD LSRII flow cytometer with an HTS system. 
For kinetic studies, BT474 cells were plated at 10,000 cells/well in a 96-well plate 
and allowed to adhere for 24 h at 37 °C and 5% CO2.  Nanoparticles in OPTI-MEM (200 
µg/mL) were incubated with cells at 37 °C and 5% CO2 for specified amounts of time 
and then removed.  Cells were then processed for flow cytometry analysis as described 
above. 
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2.3.2.11  Confocal Microscopy 
BT474 cells were plated on cover slips in a 6-well plate (5 × 104 cells/well) 
overnight at 37 °C and 5% CO2.  Cells were incubated with 50 µg/mL of nanoparticles in 
OPTI-MEM for 4 h at 37 °C.  Cells were fixed, made permeable with 0.1% triton-X100 
in PBS for 3 min, and incubated with 1 µM of TO-PRO-3 (Invitrogen) in DPBS for 15 
min.  Cells were washed with DPBS, and cover slips were mounted onto glass slides with 
FluorSave Reagent (Calbiochem), and cells were imaged with a confocal laser scanning 
microscope (Olympus Fluoview FV500). 
 
2.3.2.12  Inhibition of Cellular Internalization of Nanoparticles 
BT474 cells were plated at 10,000 cells/well in a 96-well plate and allowed to 
adhere overnight at 37 °C and 5% CO2.  Free Herceptin, heptamer, or IgG (6 µg) was 
dosed onto cells.  The cells were incubated at 37 °C for 1 h, after which free targeting 
ligands were removed.  Nanoparticles in OPTI-MEM, at 200 µg/mL, were incubated with 
cells at 37 °C for 4 h and then removed.  The cells were washed twice with DPBS, 
trypsinized, and prepared for analysis by flow cytometry with a 0.2% trypan blue solution 
containing 10% FBS in DPBS.  Samples were analyzed with a BD LSRII flow cytometer 
with an HTS system. 
 
2.3.3  Results and Discussion 
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2.3.3.1  Particle Fabrication and Noncovalent Conjugation with Herceptin/IgG 
As the PRINT technology affords independent control over particle size, shape, 
matrix, and surface chemistry,52-55,57-60,80 cylindrical (d = 200 nm and h = 200 nm) 
nanoparticles, primarily comprised of biocompatible poly(ethylene glycol) (PEG), were 
fabricated through this process (Figure 2.14). 
 
 
Figure 2.14  SEM of cylindrical (d = 200 nm and h = 200 nm) nanoparticles.  Scale bar is 
3 µm. 
 
Nanoparticles were mostly composed of the crosslinker PEG700 diacrylate, and also 2-
aminoethyl methacrylate hydrochloride for functional handles in surface modification, 
and fluorescein o-acrylate to fluorescently label nanoparticles for tracking in vitro (Table 
2.3). 
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Table 2.3  Composition of PRINT nanoparticles for targeting. 
Monomers Wt % 
PEG700 diacrylate 77 
2-Aminoethyl methacrylate hydrochloride 20 
Fluorescein o-acrylate 2 
2,2-Diethoxyacetophenone 1 
 
Cylindrical pre-functionalized nanoparticles with no surface modification had a 
hydrodynamic diameter of 288 nm with a PDI of 0.114.  As seen in Table 2.4, they also 
possessed a positive ζ-potential +26 mV.  The cationic nature of the pre-functionalized 
nanoparticles was due to amine functional groups.  Positively charged particles have been 
reported to internalize rapidly though nonspecifically into cells53,61,62 and can also induce 
cytotoxicity.63  Alternately, negatively charged particles show low intracellular 
internalization.53,61,62  Thus, for the purposes of drug delivery, nanoparticles are often 
designed to have a negative charge.  The use of negatively charged nanoparticles helps to 
minimize nonspecific uptake and in conjunction with targeting ligands, aids in achieving 
specific accumulation within the disease site.59 
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Table 2.4  Hydrodynamic diameters and zeta potentials of PRINT nanoparticles 
throughout surface modifications to noncovalently conjugate Herceptin. 
Nanoparticle Diameter (nm) PDI ζ-Potential (mV) 
Pre-functionalized 288 0.114 +26.0 ± 0.5 
Biotinylated 284 0.111 -23.6 ± 0.5 
NP-Herc 329 0.213 -20.1 ± 0.3 
NP-IgG 310 0.214 -18.7 ± 0.2 
 
Consequently, pre-functionalized nanoparticles were functionalized and 
conjugated with targeting ligands as described previously.  Pre-functionalized 
nanoparticles were reacted with NHS-PEG3400-biotin and then with acetic anhydride to 
quench any unreacted amines.  As shown in Table 2.4, biotinylated nanoparticles still 
maintained their size (284 nm) after surface modification.  However, their surface 
charges shifted to negative ζ-potentials (-23.6 mV) so as to inhibit nonspecific cellular 
internalization.  Through biotin-avidin linkages, targeting ligands were conjugated onto 
the surfaces of nanoparticles.  Biotinylated nanoparticles were first reacted with avidin 
and then with the targeting ligands biotinylated Herceptin or IgG.  Herceptin is a 
humanized monoclonal antibody that binds with HER2, while IgG is a nonspecific 
control antibody.  For Herceptin-targeted nanoparticles (NP-Herc) and IgG-targeted 
nanoparticles (NP-IgG), the ζ-potentials were negative (around -20 mV) so as to 
minimize nonspecific cellular uptake while targeting ligands could facilitate specific 
accumulation within tumor cells. 
Because Herceptin was conjugated onto nanoparticles though biotin-avidin 
linkages, it was first labeled with biotin to facilitate attachment.  Herceptin was reacted 
with NHS-PEG12-biotin, resulting in antibody that was randomly labeled with biotin.  
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The biological integrity of biotinylated Herceptin was determined prior to conjugation 
with nanoparticles.  Binding of biotinylated Herceptin with HER2 was investigated to 
ensure that antibody activity was maintained and was not disturbed by the arbitrary 
reaction with biotin.  Binding of unmodified and biotinylated Herceptin in BT474 
(human breast carcinoma) cells was studied by flow cytometry using a secondary 
antibody labeled with the fluorescent dye Alexa Fluor 488.  Shown in Figure 2.15, there 
were similar shifts in fluorescence for unmodified and biotinylated Herceptin, suggesting 
that biotinylated Herceptin maintained its activity and could still bind to the HER2 
receptor on BT474 cells.  There was also minimal nonspecific binding of the fluorescent 
secondary antibody.  Based on this data, labeling Herceptin with biotin did not adversely 
alter its binding with HER2.  That being the case, biotinylated Herceptin was used to 
functionalize and target nanoparticles. 
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Figure 2.15  Flow cytometry histograms of (A) BT474 cells, (B) binding of Herceptin, 
(C) no nonspecific of the fluorescent secondary antibody, and (D) binding of biotinylated 
Herceptin. 
 
2.3.3.2  Determination of HER2-Positive Cell Lines 
Numerous cancer cell lines were investigated for expression of the HER2 receptor.  
In a similar manner used to check the integrity of biotinylated Herceptin, HeLa (human 
cervical cancer), MCF7 (human breast adenocarcinoma), OVCAR3 and SKOV3 (human 
ovarian adenocarcinoma), and BT474 (human breast carcinoma) cells were probed for 
HER2 with Herceptin as a primary antibody and an Alexa Fluor 488 fluorescently-
labeled secondary antibody.  As shown in flow cytometry histograms in Figure 2.16, 
BT474 and SKOV3 cells strongly expressed the HER2 receptor.  HeLa, MCF7, and 
OVCAR3 cells demonstrated less intense shifts in fluorescence, indicating decreased 
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expression of the receptor.  Based on these results, BT474, SKOV3, and MCF7 cells 
were selected for further investigations with Herceptin-targeted PRINT nanoparticles. 
 
 
Figure 2.16  Flow cytometry histograms of HER2 expression in various cancer cell lines 
by labeling with Herceptin and a fluorescent (Alexa Fluor 488) secondary antibody. 
 
2.3.3.3  Cellular Internalization of Nanoparticles with Noncovalently Conjugated 
Herceptin/IgG 
Targeting specificity of nanoparticles targeted with Herceptin and IgG through 
noncovalent methods was investigated in various cancer cell lines of differing HER2 
expression.  NP-Herc and NP-IgG, in increasing concentration up to 200 µg/mL, were 
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incubated with BT474, SKOV3, and MCF7 cells for 4 h at 37 °C.  Samples were 
analyzed by a flow cytometry technique to quantify the percentage of cells with 
internalized nanoparticles.64  As seen in Figure 2.17, BT474 cells readily internalized NP-
Herc with nearly 95% of cells containing nanoparticles.  Uptake of NP-Herc was slightly 
lower in SKOV3 cells (75%), and MCF7 cells internalized a minimal amount of NP-Herc.  
This trend correlates with the expression level of the HER2 receptor in each cell line.  
BT474 cells express more HER2 receptors than SKOV3 cells, which have more HER2 
than MCF7 cells.  Increased level of cellular HER2 receptors facilitates greater 
nanoparticle internalization.  However, for NP-IgG, there was negligible accumulation in 
all cell lines (<2%).  This demonstrates the high specificity of NP-Herc as a targeted 
nanoparticle system, which can discriminate cancer cells with high overexpression of the 
HER2 receptor from those with minimal levels of the receptor. 
 
0 50 100 150 200 250
0
20
40
60
80
100
BT474;  NP-Herc
SKOV3;  NP-Herc
MCF7;  NP-Herc
BT474;  NP-IgG
SKOV3;  NP-IgG
MCF7;  NP-IgG
Particle Concentration (ug/mL)
%
 
Ce
lls
 
w
ith
 
Pa
rt
ic
le
 
Up
ta
ke
 
Figure 2.17  Cellular internalization of cylindrical 200 nm nanoparticles targeted with 
Herceptin or IgG in BT474, SKOV3, and MCF7 cells. 
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In addition to flow cytometry, targeting and internalization of 200 nm cylindrical 
NP-Herc were visualized by confocal microscopy.  Fluorescein-labeled nanoparticles 
were incubated with BT474 cells for 4 h at 37 °C.  Based on flow cytometry results, NP-
Herc were anticipated to be readily internalized into BT474 cells, and indeed, the targeted 
nanoparticles bound to the HER2 receptor and internalized into cells (Figure 2.18).  
Conjugation with the HER2 receptor presumably induced nanoparticle internalization 
through receptor-mediated endocytosis.  Targeting results from both flow cytometry and 
confocal microscopy demonstrate the potential of PRINT nanoparticles as advanced 
nanomedicine through highly specific targeting of conjugated Herceptin to the HER2 
receptor and subsequent cellular internalization in HER2-positive cells. 
 
 
Figure 2.18  Confocal microscopy images of (A) 200 nm cylindrical, fluorescein-labeled 
NP-Herc (green), (B) in BT474 cells (nuclei stained), and (C) merge of fluorescence and 
DIC. 
  
2.3.3.4  Effect of Targeting Ligand Density on Targeted Cellular Internalization 
The density of Herceptin on the nanoparticle surface was varied to further 
understand targeting specificity.  Density was modulated from 100% of Herceptin to 0%, 
B C A 
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with the total ligand concentration maintained by substituting Herceptin for the IgG 
control antibody.  In other words, nanoparticles with 0% Herceptin were equivalent to 
nanoparticles with 100% of IgG (NP-IgG).  Cells were incubated for 4 h at 37 °C with 
targeted nanoparticles (0-200 µg/mL) with varied ligand densities.  In BT474 cells, all 
nanoparticles with Herceptin exhibited selective internalization in a dose dependent 
manner, while nanoparticles with 0% Herceptin (or NP-IgG) had negligible uptake 
(Figure 2.19).  Over 85% of BT474 cells readily internalized nanoparticles with just 50% 
of Herceptin, achieving a similar uptake profile as nanoparticles with 75% and 100% of 
Herceptin.  However, when the targeting antibody Herceptin accounted for only 25% of 
the ligands, cellular uptake decreased slightly to 75%.  Nonetheless, all nanoparticles 
conjugated with some Herceptin specifically internalized into BT474 cells because of the 
overexpression of cellular HER2 receptor, while nanoparticles with 0% of Herceptin (or 
NP-IgG) demonstrated minimal uptake as a result of a negative ζ-potential and 
nonspecific control ligand.  Through this study, the high specificity and cellular 
internalization of nanoparticles with only 25% of Herceptin are promising indications for 
multimeric targeting of other overexpressed receptors to increase target specificity (i.e., 
nanoparticles with various ligands that target the HER2 and FR) or for addition of ligands 
with therapeutic effects (i.e, chemotherapeutic drugs).  
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Figure 2.19  Internalization of 200 nm cylindrical nanoparticles targeted with varied 
densities of Herceptin in BT474 cells. 
 
Cellular uptake of these nanoparticles was further investigated in MCF7 cells, 
which have a differing level of HER2 than BT474 cells.  As seen in Figure 2.20, less than 
20% of MCF7 cells internalized nanoparticles labeled with any Herceptin.  In fact, 
minimal differences in uptake were observed amongst nanoparticles targeted with 100%, 
75%, 50%, or 25% of Herceptin.  Low cellular uptake of these nanoparticles can be 
attributed to the minimal expression of the HER2 receptor in MCF7 cells.  Based on 
nanoparticle internalization in BT474 and MCF7 cells, the extent of uptake of NP-Herc 
correlates well with the cellular expression of the HER2 receptor.  This demonstrates the 
high degree of specificity with which PRINT nanoparticles functionalized with Herceptin 
can target diseased cells. 
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Figure 2.20  Internalization of 200 nm cylindrical nanoparticles targeted with varied 
densities of Herceptin in MCF7 cells. 
 
2.3.3.5  Particle Fabrication and Covalent Conjugation of Ligands Targeting HER2 
In efforts to further understand the targeting of nanoparticles, 200 nm cylindrical 
nanoparticles were functionalized with Herceptin and an engineered heptameric ligand, 
both with binding affinity to the HER2 receptor.  Similar to previous NP-Herc, these 
nanoparticles were composed of PEG700 diacrylate, 2-aminoethyl methacrylate, and 
fluorescein o-acrylate (Table 2.3).  Pre-functionalized nanoparticles without surface 
modifications had a hydrodynamic diameter of 295 nm and were positively charged 
(+32.4 mV, Table 2.5). 
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Table 2.5  Hydrodynamic diameters and zeta potentials of 200 nm cylindrical PRINT 
nanoparticles for targeting with HER2 ligands. 
Nanoparticle Diameter (nm) PDI ζ-Potential (mV) 
Pre-functionalized 295 0.080 +32.4 ± 0.2 
Maleimide 300 0.017 -31.3 ± 0.6 
NP-7mer 301 0.062 -34.2 ± 2.8 
NP-Herc 299 0.125 -31.8 ± 0.6 
NP-IgG 298 0.058 -32.8 ± 0.4 
 
However, positive ζ-potentials can induce nonspecific cellular uptake of particles53,61,62 
and also cellular toxicity,63 so pre-functionalized nanoparticles were functionalized for a 
negative ζ-potential and conjugated with targeting ligands for the HER2 receptor.  Unlike 
previously fabricated targeted PRINT nanoparticles, targeting ligands were covalently 
attached to the surface of nanoparticles through maleimide functional groups (Figure 
2.21).  Pre-functionalized nanoparticles were reacted with NHS-PEG5000-maleimide, 
yielding nanoparticles with surface maleimide functional groups for further reaction with 
targeting ligands.  After quenching unreacted amines with acetic anhydride, maleimide 
nanoparticles became negatively charged (-31.3 ± 0.6 mV) so as to minimize nonspecific 
cellular internalization.  Maleimide nanoparticles were then reacted with lysines in 
Herceptin or IgG under moderately basic conditions (pH 8.5) for covalent but arbitrary 
attachment of the antibodies.  Conversely, maleimide nanoparticles were reacted under 
neutral conditions (pH 7.4) with heptameric ligands (7mer) consisting of a cysteine for 
site specific covalent conjugation of targeting ligands.  Heptamer-targeted nanoparticles 
(NP-7mer), along with covalently linked NP-Herc and NP-IgG, maintained 
hydrodynamic diameters around 300 nm and negative ζ-potentials around -30 mV. 
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Figure 2.21  Scheme of covalent conjugation of HER2 targeting ligands to the surface of 
nanoparticles.  (A) Functionalizing pre-functionalized nanoparticles for surface 
maleimide functional groups.  (B) Conjugating maleimide nanoparticles with targeting 
ligands. 
 
2.3.3.6  Cellular Targeting of Nanoparticles with Covalently Conjugated Ligands 
Nanoparticles were investigated in BT474 breast cancer cells for the effects of 
surface modification through covalent linkages and the targeting of the engineered 
heptameric ligand with seven sites for binding with HER2 receptors.  After incubation 
with cells for 4 h at 37 °C, samples were analyzed by flow cytometry.  HER2 receptor 
targeting nanoparticles NP-7mer and NP-Herc were internalized into cells, while NP-IgG 
showed minimal cellular uptake of <10% (Figure 2.22).  About 80% of BT474 cells 
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internalized NP-7mer, while fewer cells (~40%) internalized NP-Herc, but both NP-7mer 
and NP-Herc demonstrated target specificity, binding to the HER2 receptor present on 
BT474 cells to induce internalization.  Interestingly, NP-Herc fabricated through covalent 
conjugation methods did not achieve similar levels of cellular internalization as NP-Herc 
prepared through noncovalent biotin-avidin linkages (40% vs. 85%).  However, NP-7mer 
reached 80% uptake in BT474 cells, comparable to NP-Herc formed with noncovalent 
bonds. 
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Figure 2.22  Internalization of nanoparticles targeted with HER2 ligands or IgG in 
BT474 cells. 
 
A possible explanation for this is the accelerated internalization of large cellular surface 
complexes formed by neighboring HER2 receptors interconnected by proteins (Figure 
2.23).81-83 
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Figure 2.23  Models comparing the size of receptor-antibody complexes formed at 
cellular surfaces by (A) one or (B) two antibodies.  Adapted from [81]. 
 
The heptamer can bind with up to seven HER2 receptors, while Herceptin can only bind 
with a maximum of two receptors.  With multiple copies of the heptameric ligand, NP-
7mer possess over three times as many binding sites for HER2 as NP-Herc.  The 
increased valency of NP-7mer enables larger cellular surface complexes to be formed, 
and thus, facilitates internalization of the nanoparticles.  Similarly, NP-Herc fabricated 
through biotin-avidin linkages likely formed large receptor-antibody complexes that 
enabled efficient uptake of nanoparticles because of their increased multivalent nature 
over NP-Herc prepared by covalent means (Figure 2.24). 
 
 
(A) (B) 
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Figure 2.24  Diagrams illustrating the maximal valency of NP-Herc and NP-7mer. 
 
Additionally, specific targeting of NP-7mer and NP-Herc was visualized by 
confocal microscopy.  NP-7mer, NP-Herc, and NP-IgG, all labeled with fluorescein, were 
incubated with BT474 cells.  As expected, cells internalized NP-7mer, as observed by 
intracellular nanoparticle fluorescence seen in green (Figure 2.25), corroborating results 
from flow cytometry.  These targeted nanoparticles bound to the HER2 receptor on 
BT474 cells, thus inducing receptor-mediated endocytosis.  In contrast, NP-Herc were 
mostly observed at the periphery of cells, bound to the HER2 receptor but not 
internalized because the HER2 receptor is remarkably resistant to internalization.84,85  
Also, the low multivalent nature of NP-Herc relative to NP-7mer likely could not create 
sufficiently large antigen-antibody complexes to induce efficient internalization.  As a 
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control, NP-IgG showed negligible internalization into cells due to their negative surface 
charge and nonspecific ligand. 
 
 
Figure 2.25  Confocal micrscopy images of BT4747 cells with (A) NP-Herc, (B) NP-
7mer, and (C) NP-IgG. 
 
2.3.3.7  Kinetics of Internalization of Nanoparticles with Covalently Conjugated 
Ligands 
To further elucidate the effect of surface chemistry and targeting ligands, the 
kinetics of internalization of these nanoparticles were investigated by flow cytometry.  
Targeted nanoparticles were incubated with BT474 cells at 37 °C for varied periods up to 
4 h.  NP-7mer internalized into cells more rapidly than NP-Herc.  Different ligands, both 
targeting the HER2 receptor, resulted in dissimilar rates of nanoparticle uptake into 
BT474 cells.  This is a result of the differing valency between the two targeted 
nanoparticles, which influences the size of the HER2 receptor-ligand complexes on the 
cellular surface.  Previous studies have shown that the rate of internalization is 
proportional to the size of HER2-ligand lattices.81,82  As NP-7mer are capable of binding 
more receptors and thus forming larger cellular surface complexes than NP-Herc, it is 
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expected and was observed that the rate of internalization of NP-7mer is more rapid than 
NP-Herc. 
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Figure 2.26  Kinetics of internalization of nanoparticles conjugated with ligands for 
HER2 or IgG in BT474 cells. 
 
2.3.3.8  Competition with Free Targeting Ligands 
Additionally, the effect of competing free targeting ligands on internalization of 
targeted nanoparticles was investigated in BT474 cells.  To confirm binding and uptake 
of NP-Herc and NP-7mer, BT474 cells were initially incubated with free Herceptin prior 
to exposure to nanoparticles (200 µg/mL) to allow the free ligands to bind to the HER2 
receptors on the cellular surface, decreasing receptors available for the nanoparticles.  
Internalization of NP-Herc was greatly inhibited when cells were incubated with free 
Herceptin (Figure 2.26), indicating that NP-Herc are binding to the HER2 receptor and 
inducing receptor-mediated endocytosis.   However, for NP-7mer, cellular uptake was 
only slightly inhibited with a drop of 80% to about 70% of cells with internalized 
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nanoparticles, indicating that the heptameric ligand does not bind the same epitope on the 
HER2 receptor as Herceptin.  Control NP-IgG were unaffected by the addition of free 
Herceptin and exhibited minimal cellular uptake. 
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Figure 2.27  Effect on internalization of targeted nanoparticles in BT474 cells with prior 
exposure to free Herceptin. 
 
Because internalization of NP-7mer was minimally affected by free Herceptin, 
BT474 cells were also incubated with free heptamer before addition of nanoparticles.  In 
this case, internalization of NP-7mer was inhibited to <50% (Figure 2.28), indicating that 
NP-7mer are also internalized through a receptor-mediated mechanism despite binding to 
the HER2 receptor in a different site than Herceptin.  Interestingly, when BT474 cells 
were incubated with free heptamer prior to the addition of nanoparticles, internalization 
of NP-Herc and NP-IgG increased to 60% and 35%, respectively. 
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Figure 2.28  Effect on internalization of targeted nanoparticles in BT474 cells with prior 
exposure to free heptamer. 
 
The heptameric ligand can bind up to seven HER2 receptors to generate large cellular 
lattices of receptors and ligands.  Seen previously, the cellular surface complexes formed 
by NP-7mer accelerate internalization.  As the heptamer and Herceptin bind different 
epitopes of HER2, NP-Herc can bind to receptors within a cellular surface complex 
interconnected by heptameric ligands, thereby enhancing internalization of NP-Herc.  
Increased cellular uptake of NP-IgG was likely triggered by the same mechanism where 
large, preformed antigen-heptamer complexes heightened any nonspecific binding of NP-
IgG.  Similar results of enhanced HER2 receptor internalization have been reported in 
which BT474 cells incubated with antibodies that bind different epitopes stimulate 
internalization because of the formation of larger antigen-antibody complexes.81  
Targeting nanoparticles with multivalent ligands can trigger alternate cellular pathways 
that intensify the accumulation and potency of nanoparticle therapeutics. 
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2.3.4  Conclusions 
Through the PRINT technology, HER2 receptor targeting nanoparticles were 
successfully designed and fabricated to study the potential of these nanoparticles for a 
targeted delivery system and the effects of multivalency on targeting.  Nanoparticles 
possessed a negative surface charge that avoided nonspecific cellular uptake, but through 
noncovalent and covalent methods, Herceptin and heptameric ligands were conjugated to 
nanoparticles, enabling specific targeting and HER2 receptor-mediated endocytosis, 
despite the receptor’s resistance to internalization.  Cellular uptake of targeted 
nanoparticles was found to be dose dependent and also correlated with the expression 
level of the HER2 receptor in the cells.  Furthermore, the multivalent nature of targeted 
nanoparticles influenced cellular targeting and internalization.  When Herceptin was 
noncovalently conjugated onto nanoparticles, NP-Herc achieved high levels of uptake in 
BT474 cells through the numerous ligands on the surface from the multiple biotin 
binding sites.  Similar levels of cellular uptake were achieved with NP-7mer because of 
the multivalency of the heptameric ligand that could bind and form large antigen-ligand 
complexes at the cellular surface.  Thus, nanoparticles targeted with HER2 ligands 
demonstrate potential as improved therapeutics through specific targeting and induced 
internalization.  
 
2.3.5  Future Work 
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2.3.5.1  Nanoparticles Targeting the HER2 Receptor 
A barrier for delivery of nanoparticles is the length of in vivo circulation.  Smaller 
spherical particle sizes from micro to nano have been found to increase circulation.86,87  
However, filamentous particles (>5 µm) were recently reported to have long circulation 
in vivo, detectable up to a week after injection.88,89  Also, data indicates that cellular 
uptake by macrophages is decreased with elongated particles relative to spherical 
structures, thus indicating a method of reducing clearance by the reticuloendothelial 
clearance pathways so as to prolong circulation.90-92  Thus, these properties of 
filamentous particles in conjunction with specific targeting may unlock great potential for 
therapeutic delivery of nanoparticles.  To better elucidate the possibilities of 
nanoparticles targeted with HER2 ligands as improved nanotherapeutics, Herceptin-
targeted cylindrical nanoparticles (d = 200 nm and h = 200 nm, AR = 1) were compared 
with elongated, rod-like nanoparticles (80 × 320 nm, AR = 4).  Targeting ligands were 
conjugated via biotin-avidin linkages.  NP-Herc and NP-IgG, in various nanoparticle 
concentrations of 0-200 µg/mL, were incubated with cancer cell lines of differing 
expression levels of the HER2 receptor.  In BT474 cells, both types of NP-Herc exhibited 
similarly specific and high internalization around 90%, while there was an inconsiderable 
amount of cells with uptake of NP-IgG for either nanoparticle shape (Figure 2.29). 
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Figure 2.29  Internalization of 200 nm cylindrical and 80 × 320 nm rod-like 
nanoparticles targeted with either Herceptin or IgG in BT474 cells. 
 
In MCF7 cells, negligible difference in cellular uptake was observed between NP-
Herc and NP-IgG (Figure 2.30).  Less than 5% of MCF7 cells internalized any 
nanoparticles regardless of shape, aspect ratio, or surface ligands.  This can be attributed 
to the minimal expression of the HER2 receptor in MCF7 cells. 
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Figure 2.30  Internalization of 200 nm cylindrical and 80 × 320 nm rod-like 
nanoparticles targeted with either Herceptin or IgG in MCF7 cells. 
 
Regardless of the nanoparticle shape and aspect ratio, it was found that the extent of 
internalization of NP-Herc correlated well with the cellular level of the HER2 receptor.  
BT474 cells possess high amplification of the HER2 receptor so demonstrated increased 
nanoparticle uptake, whereas MCF7 cells, with low expression of HER2, exhibited low 
uptake of all nanoparticles.  This indicates the high specificity of NP-Herc for binding to 
the HER2 receptor for cellular internalization despite elongated, nonspherical shapes as 
minimal differences in cellular uptake were observed between 200 nm cylindrical and 80 
× 320 nm rod-like nanoparticles. 
The effect of nanoparticle shape and aspect ratio on the kinetics of cellular 
internalization was also investigated.  Targeted nanoparticles were incubated with BT474 
and MCF7 cells at 37 °C and then analyzed for cellular uptake by flow cytometry at 
various time points (0-4 h).  Shown in Figure 2.31, internalization of NP-Herc of either 
shape followed nearly identical profiles over the course of 4 h in BT474 cells.  Control 
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NP-IgG of both shapes in BT474 cells also exhibited very low uptake throughout 4 h.  In 
MCF7 cells, due to the low expression of the HER2 receptor, there was minimal uptake 
of both NP-Herc and NP-IgG in either shape over the time course. 
 
 
Figure 2.31  Kinetics of internalization of 200 nm cylindrical and 80 × 320 nm rod-like 
NP-Herc and NP-IgG in (A) BT474 and (B) MCF7 cells. 
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These preliminary results suggest that, in this size range, targeted nanoparticles are 
minimally influenced by the shape or aspect ratio in regards to cellular uptake and 
kinetics.  Instead, the predominant factor affecting cellular uptake of NP-Herc is the 
expression level of the HER2 receptor in diseased cells because nanoparticle 
internalization is regulated by HER2 receptor-mediated endocytosis.  Further studies 
would be necessary to fully elucidate the effects of particle shape and size, but initial 
results are promising for the application of nonspherical nanoparticles as advanced 
targeted nanotherapeutics.  Additional nanoparticle shapes and sizes should be 
investigated, specifically nanoparticles with greater aspect ratios, such as filamentous 80 
× 2000 nm (AR = 25) or 80 × 5000 nm (AR = 62.5) nanoparticles.  Targeting capabilities 
of these nanoparticles must be affirmed, in addition to in vivo pharmacokinetics resulting 
from the varied sizes to determine whether targeted filamentous particles exhibit similar 
prolonged circulation and accumulation at the tumor site as compared to untargeted 
counterparts. 
 
2.3.5.2  Nanoparticles Targeting the HER1 Receptor 
With the success of targeting PRINT nanoparticles with heptameric ligands for 
the HER2 receptor, targeting the HER1 receptor (EGFR, ErbB1), another member of the 
epidermal growth factor receptor family, was investigated.  The HER1 receptor is 
overexpressed in 20-80% of breast cancers, among others, and both HER1 and HER2 
receptor drive growth and progression of tumors.31,93-95  Cylindrical nanoparticles (d = 
200 nm and h = 200 nm) were covalently conjugated with engineered heptameric ligands 
(provided by Professor Rihe Liu from the UNC Eshelman School of Pharmacy) or 
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nonspecific control IgG.  Targeted nanoparticles were incubated with A431 (epidermoid 
carcinoma) and SKOV3 (human ovarian adenocarcinoma) cells for 4 h at 37 °C.  As seen 
in Figure 2.32, over 90% of A431 cells specifically internalized NP-7mer because of the 
high expression level of the HER1 receptor.  However, NP-7mer did not exhibit 
significant cellular uptake in SKOV3 cells because of minimal expression of the receptor.  
For NP-IgG, there was low uptake in both cell lines as a result of the nonspecific ligand 
and negative surface charge. 
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Figure 2.32  Cellular internalization of cylindrical nanoparticles targeted with heptameric 
ligands for the HER1 receptor or IgG in A431 and SKOV3 cells. 
 
Selective internalization of NP-7mer was also observed by confocal microscopy 
(Figure 2.33).  NP-7mer, labeled with fluorescein, were prevalent throughout A431 cells 
as the nanoparticles bound to the HER1 receptor and were presumably internalized 
through receptor-mediated endocytosis.  Conversely, NP-IgG were minimally 
internalized. 
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Figure 2.33  Confocal microscopy images of (A) HER1 NP-7mer (green) and (B) NP-
IgG in A431 cells. 
 
These promising preliminary in vitro results from targeting with heptameric ligands for 
the HER1 receptor demonstrate the versatility of PRINT nanoparticles to be designed and 
fabricated to accommodate specific targets and diseases.  Further investigation into HER1 
targeting is necessary to confirm the target specificity of the nanoparticles, such as 
competition with free ligand as well as comparison to the approved monoclonal antibody 
against HER1, Erbitux (cetuximab).  Furthermore, the multivalency of these 
nanoparticles may allow for the presence of various targeting agents (i.e., HER2 
heptameric ligand, Herceptin, antibodies against the FR or TfR) on the nanoparticle 
surface to enhance target specificity for drug delivery, or therapeutic agents, such as 
chemotherapeutic drugs, can be conjugated to the nanoparticle surface while maintaining 
high specificity for tumor cells.  Additional research is required to determine the potential 
of these nanoparticles as improved targeted drug delivery agents. 
(A) (B) 
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 CHAPTER 3 
ENGINEERED TARGETED PRINT® NANOPARTICLES FOR DRUG DELIVERY 
 
3.1  Degradable Silyl Ether Nanoparticles 
 
3.1.1  Introduction 
Numerous advancements have emerged in the development of engineered drug 
delivery nanocarriers for more effective cancer therapeutics.  Improvements include 
stimuli-responsive drug delivery agents that achieve better targeted efficiency and 
treatment efficacy of the chemotherapeutic.1  Researchers have developed sophisticated 
systems that undergo cleavage or degradation catalyzed by biological triggers such as 
temperature and pH.2-5  In particular, hydrazones,6-8 trityls,9 aconityls,10,11 vinyl 
ethers,12,13 polyketals,14,15 acetals,16 poly(ortho esters),17 and thiopropionates18 exploit a 
pH gradient to trigger degradation.  However, these materials are limited by poor 
tunability, toxic degradation prodructs, or complex syntheses. 
Thus, we reported the development of silyl ether-based biomaterials that are 
sensitive to pH.19  Silyl ethers are commonly employed as protecting groups in organic 
chemistry because the rate of deprotection can be tuned by varying the substituents on the 
silicon atom.20  Less hindered substituents create silyl ethers that are more susceptible to 
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acid catalyzed hydrolysis.  For instance, the relative stabilities of trimethyl silyl ether 
(TMS), triethyl silyl ether (TES), and triisopropyl silyl ether (TIS) to acid catalyzed 
hydrolysis are 1, 64, and 700,000, respectively (Table 3.1).20 
 
Table 3.1  Chemical structures of silyl ethers and their relative stabilities to acid 
catalyzed hydrolysis. 
 
Trimethyl silyl ether 
(TMS) 
Triethyl silyl ether 
(TES) 
Triisopropyl silyl 
ether (TIS) 
Chemical Structure R O Si
 
R O Si
 
R O Si
 
Relative Stability 1 64 700,000 
 
This example shows that the rate of deprotection can range over multiple orders of 
magnitude by merely modifying the substituents on the silicon atom.  More specifically, 
bifunctional silyl ethers, which consist of a C—O—Si(R)2—O—C moiety, are commonly 
used for the protection of 1,2- and 1,3-diols.21-23  Typically, less hindered substituents, 
such as dimethyl, diethyl, and diisopropyl, are not utilized because they are excessively 
sensitive to acid catalyzed hydrolysis and thus, are not appropriate as protecting groups.  
However, these same properties can be favorable for acid sensitive biomaterials.  As such, 
silyl ether chemistry was adapted to create stimuli-responsive materials for biomedical 
purposes. 
Bifunctional silyl ether crosslinkers (Figure 3.1) were easily synthesized in one 
step from commercially available reagents to generate a collection of crosslinkers with 
varied substituents on the silicon atom.19  Crosslinkers were named according to their 
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substituents: dimethyl silyl ether (DMS), diethyl silyl ether (DES), diisopropyl silyl ether 
(DIS), and di-tert-butyl silyl ether (DTS). 
 
O
O O Si
R
R
O O
O R = Me (DMS)
Et (DES)
iPr (DIS)
tBu (DTS)
 
Figure 3.1  Generic chemical structure of silyl ether crosslinker. 
 
These materials were used to fabricate microparticles by the PRINT process, and the 
particles were investigated for drug delivery purposes.  When 5 µm cubic particles were 
studied under varying pHs, it was found that all particles preferentially degraded under 
the acidic pH 5.0 and more slowly under the neutral pH 7.4.  This indicates that the 
particles, fabricated from the acid-sensitive crosslinkers, are more susceptible to 
degradation under endosomal conditions rather than physiological environments.  
Additionally, particles fabricated from the DMS crosslinker displayed an accelerated rate 
of degradation in just hours, while particles fabricated from the DES crosslinker degraded 
on the order of days.  Particles fabricated from the DIS crosslinker exhibited an even 
slower rate of degradation over months.  This demonstrates that the rate of degradation 
was effectively modulated by altering the substituent on the silicon atom of the silyl ether 
crosslinker. 
Furthermore, the intracellular degradation of 3 µm hexnut particles prepared from 
the DMS and DTS crosslinkers was investigated with HeLa (human cervical cancer) cells.  
Particles prepared from the acid-sensitive DMS crosslinker degraded rapidly under 
intracellular conditions, initially swelling and deforming, and then fragmenting before 
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complete degradation, as observed by the growing widespread green fluorescence within 
the cells by confocal microscopy (Figure 3.2).  In contrast, particles fabricated from the 
nondegrading DTS crosslinker exhibited no change under the same intracellular 
environment.  This illustrates the potential of the crosslinkers as biomaterials for drug 
delivery carriers because the materials degrade under intracellular conditions and thus, 
may deliver chemotherapeutics more effectively within cancer cells. 
 
 
Figure 3.2  Confocal imcroscopy images of the phases of rapid degradation of DMS 
particles (green): (a) swelling, (b) fragmentation, and (c) complete degradation.  DTS 
particles (red) exhibited no change intracellularly (d).  Scale bars = 10 µm.19 
 
Based on the promising results of these bifunctional silyl ether crosslinkers, 
additional crosslinkers incorporating PEG (poly(ethylene glycol)) were synthesized.  
PEG is a biocompatible material and imparts hydrophilicity.  This new class of 
bifunctional silyl ether crosslinkers was studied as biomaterials for improved drug 
delivery agents.  Specifically, the PEG8DES (PEG8 diethyl silyl ether) and PEG8DTS 
(PEG8 di-tert-butyl silyl ether) crosslinkers were investigated (Figure 3.3). 
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Figure 3.3  Chemical structures of the PEG8DES (top) and PEG8DTS (bottom) silyl ether 
crosslinkers. 
 
These materials were investigated with the chemotherapeutic agent docetaxel, which is 
the active component in Taxotere.  Taxotere is a versatile therapeutic drug approved for 
the treatment of a variety of cancers, including breast, non-small cell lung, prostate, 
gastric, and head and neck.24  By combining the acid-sensitive characteristics of the silyl 
ether-based crosslinkers along with active targeting ligands, we aimed to develop 
improved nanoparticulate cancer therapeutics that specifically treat diseased cells by 
intracellular degradation of the drug carrier and subsequent release of the drug docetaxel. 
 
3.1.2  Experimental 
 
3.1.2.1  Chemicals and Reagents 
Biotinylated OKT9 and isotype control mouse IgG were purchased from 
eBioscience.  Herceptin (Genentech) was purchased from the UNC Hospitals.  
UltraAvidin was purchased from Leinco Technologies.  Biotin-poly(ethylene glycol)-
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succinimidyl carboxymethyl ester (3400 g/mol for PEG; NHS-PEG3400-biotin) was 
purchased from Laysan Bio.  Anhydrous dimethylformamide (DMF) and pyridine were 
purchased from Acros.  Acetic anhydride was purchased from Fisher Scientific.  All other 
reagents were purchased from Sigma Aldrich. 
 
3.1.2.2  Cells and Culture 
Ramos, BT474, HeLa, and H460 cells were from UNC LCCC Tissue Culture 
Facility.  Ramos and H460 cells were maintained in RPMI 1640 with 10% FBS.  BT474 
cells were maintained in RPMI 1640 with 10% FBS, 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, and 0.02 mg/mL human insulin.  
HeLa cells were maintained in MEM with 10% FBS.  All media and supplements were 
from Gibco. 
 
3.1.2.3  Fabrication of PRINT Nanoparticles 
Cylindrical nanoparticles (d = 200 nm and h = 200 nm) were fabricated using the 
PRINT technique.  Nanoparticles were prepared from a starting monomer solution (5% 
wt/vol in isopropanol) consisting of 87 wt % of bifunctional silyl ether PEG8DES or 
PEG8DTS crosslinker, 10 wt % of 2-aminoethyl methacrylate hydrochloride, 2 wt % of 
fluorescein o-acrylate, and 1 wt % of 2,2-diethoxyacetophenone.  A monomer film was 
cast upon a sheet of poly(ethylene terephthalate) (PET) by spreading 90 µL of monomer 
solution with a mayer rod (#2, R.D. Specialties), and it was dried with cool air using a 
heat gun to remove the solvent isopropanol.  The monomer film and humidified patterned 
mold, provided by Liquidia Technologies, were laminated together under pressure (40 
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PSI) and then delaminated, by gently splitting the mold and PET, to yield a mold with 
filled cavities.  The filled mold was laminated with a fresh sheet of PET and then exposed 
to UV irradiation (λ = 365 nm, power 90 mW/cm2) for 4 min under a nitrogen purge.  
The mold was removed, leaving nanoparticles transferred on the sheet of PET.  This was 
due to the higher surface energy of the PET.  Cold Dulbecco’s phosphate buffered saline 
(DPBS; 400 µL) was placed on the PET, and nanoparticles were collected mechanically 
with a cell scraper.  The harvested particles were washed twice with cold DPBS by 
centrifugation. 
 
3.1.2.4  Fabrication of Docetaxel Encapsulated PRINT Nanoparticles 
The same fabrication procedure as described for blank nanoparticles was followed.  
The nanoparticles were prepared from a starting monomer solution (5% wt/vol in 
isopropanol) consisting of 86 wt % of bifunctional silyl ether PEG8DES or PEG8DTS 
crosslinker, 10 wt % of 2-aminoethyl methacrylate hydrochloride, 2 wt % of fluorescein 
o-acrylate, 1 wt % of 2,2-diethoxyacetophenone, and either 1 wt % of docetaxel. 
 
3.1.2.5  Herceptin/OKT9/IgG Conjugation to PRINT Nanoparticles 
Nanoparticles were conjugated with Herceptin, OKT9, or IgG through a biotin-
avidin linkage.  Nanoparticles in anhydrous DMF (500 µL at 2 mg/mL) were reacted with 
5 mg of NHS-PEG3400-biotin in the presence of 10 µL anhydrous of pyridine; the 
nanoparticle dispersion was shaken on a vortex for 2 h.  Acetic anhydride (10 µL) was 
added to the dispersion, which was shaken for 10 min, to quench unreacted amines on the 
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nanoparticle surface.  The nanoparticles were washed twice with cold DPBS by 
centrifugation.  UltraAvidin (50 µL, 10 mg/mL) was added to the nanoparticles in DPBS 
(2 mg/mL).  The dispersion was shaken for 1 h.  The nanoparticles were washed twice 
with cold DPBS by centrifugation.  To target the nanoparticles, 50 µg of Herceptin, 
OKT9, or IgG was added to the nanoparticle dispersion and was shaken for 30 min at 
room temperature and then kept overnight at 4 °C.  The nanoparticles were washed twice 
with cold DPBS by centrifugation and then resuspended in DPBS. 
 
3.1.2.6  Physical Characterization of Nanoparticles 
Scanning electron microscopy samples were prepared by pipetting 10 µL of 
nanoparticle solution onto a glass slide.  Samples were dried and coated with 2 nm of 
gold palladium with a Cressington 108 auto sputter coater (Cressington Scientific 
Instruments).  Samples were imaged with a scanning electron microscope (Hitachi S-
4700).  The size (dynamic light scattering, DLS) and charge (ζ-potential) of the 
nanoparticles were determined for 20 µg/mL nanoparticle samples in a 1 mM potassium 
chloride solution with a Malvern Instruments Nano ZS. 
 
3.1.2.7  Quantitative In Vitro Cellular Targeting 
BT474, HeLa, and H460 cells were plated at 10,000 cells/well in a 96-well plate 
and allowed to adhere overnight at 37 °C and 5% CO2.  Ramos cells were used at 
100,000 cells/well.  Nanoparticles in OPTI-MEM were incubated with cells at 37 °C and 
5% CO2 for specified amounts of time and then removed.  The cells were washed twice 
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with DPBS, trypsinized, and prepared for analysis by flow cytometry with a 0.2% trypan 
blue solution containing 10% FBS in DPBS.  Samples were analyzed with a Dako CyAn 
flow cytometer. 
 
3.1.2.8  Confocal Microscopy 
BT474 cells were plated on cover slips in a 6-well plate (5 × 104 cells/well) 
overnight at 37 °C and 5% CO2.  Cells were incubated with 50 µg/mL of nanoparticles in 
OPTI-MEM for 4 h at 37 °C.  Cells were fixed, made permeable with 0.1% triton-X100 
in PBS for 3 min, and incubated with Alexa Fluor 555 phalloidin (Invitrogen) for 1 h at 
room temperature without light.  Cells were washed with DPBS, and cover slips were 
mounted onto glass slides with FluorSave Reagent (Calbiochem), and cells were imaged 
with a confocal laser scanning microscope (Olympus Fluoview FV500). 
 
3.1.2.9  Cytotoxicity of Silyl Ether-Based Nanoparticles 
BT474, HeLa, and H460 cells were plated at 5,000 cells/well in a 96-well plate 
and allowed to adhere overnight at 37 °C and 5% CO2.  Nanoparticles in complete media 
were incubated with cells at 37 °C and 5% CO2 for 72 h and removed.  Cell viability was 
determined using Promega CellTiter-Glo® Luminescent Cell Viability Assay according to 
the manufacturer’s instructions.  Bioluminescence was measured by a SpectraMax M5 
plate reader (Molecular Devices). 
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3.1.3  Results and Discussion 
 
3.1.3.1  Nanoparticle Fabrication and Conjugation with Herceptin/OKT9/IgG 
The PRINT technology is a versatile technique for the fabrication of particles.  
Previously described,19,25-32 it affords absolute control over particle size, shape, 
composition, and surface chemistry.  As such, the process was easily adapted for the 
fabrication of nanoparticles composed of novel crosslinkers consisting of bifunctional 
silyl ethers, PEG8 diethyl silyl ether (PEG8DES) and PEG8 di-tert-butyl silyl ether 
(PEG8DTS; Figure 3.3).  Cylindrical nanoparticles (d = 200 nm and h = 200 nm), 
comprised mostly of the novel silyl ether crosslinkers, were fabricated.  PEG8DES served 
as an acid sensitive nanoparticle matrix, while PEG8DTS acted as the stable, 
nondegradable control.  In addition to the crosslinker, 2-aminoethyl methacrylate 
hydrochloride, fluorescein o-acrylate, and 2,2-diethyoxyacetophenone were included 
within the nanoparticles (Table 3.2). 
 
Table 3.2  Composition of bifunctional silyl ether-based nanoparticles. 
Monomers Wt % 
PEG8DES or  PEG8DTS 87 
2-Aminoethyl methacrylate hydrochloride 10 
Fluorescein o-acrylate 2 
2,2-Diethoxyacetophenone 1 
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Amine functional handles for nanoparticle surface modification were incorporated into 
the nanoparticles through 2-aminoethyl methacrylate hydrochloride, while fluorescein o-
acrylate provided a fluorescent label so that the nanoparticles could be visualized and 
tracked with cells in vitro.  As seen in Figure 3.4, nanoparticles composed of the novel 
silyl ether crosslinkers were successfully fabricated. 
 
 
Figure 3.4  SEMs of cylindrical 200 nm (A) PEG8DES and (B) PEG8DTS nanoparticles.  
Scale bar is 3 µm. 
 
Both crosslinkers polymerized with co-monomers to form isolated cylindrical 
nanoparticles, demonstrating the versatility of the PRINT technology to fabricate 
particles composed of a desired material so as to elicit specific behaviors, properties, or 
traits in the particles. 
Unmodified, pre-functionalized nanoparticles fabricated from the PEG8DES and 
PEG8DTS crosslinkers had a hydrodynamic diameter around 300 nm and a positive ζ-
potential of approximately +26 mV (Table 3.3).  Amines from the monomer 2-
aminoethyl methacrylate hydrochloride imparted the cationic nature of the pre-
functionalized nanoparticles and were reacted with NHS-PEG3400-biotin to functionalize 
(A) (B) 
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the nanoparticles for targeting as previously described.  In order to avoid nonspecific 
cellular uptake of positively charged particles, unreacted amines were quenched with 
acetic anhydride to ensure a negative ζ-potential of -12.0 ± 0.2 mV and -14.5 ± 0.4 mV 
for nanoparticles prepared from the PEG8DES and PEG8DTS crosslinkers, respectively.  
After conversion to a negative charge, biotinylated nanoparticles were targeted with 
monoclonal antibodies through noncovalent biotin-avidin linkages.  Avidin was first 
coupled to the surface of the nanoparticles, followed by the targeting ligands Herceptin, 
OKT9, or IgG to yield Herceptin-targeted nanoparticles (NP-Herc), OKT9-targeted 
nanoparticles (NP-OKT), and IgG-targeted nanoparticles (NP-IgG), respectively.  Final 
targeted nanoparticles (NP-Herc, NP-OKT9, NP-IgG) maintained negative ζ-potentials.  
Also, throughout the surface functionalization and targeting of these silyl ether-based 
nanoparticles, the size of the nanoparticles was maintained around ~300 nm. 
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Table 3.3  Hydrodynamic diameters and zeta potentials of cylindrical 200 nm PEG8DES 
and PEG8DTS nanoparticles. 
Silyl Ether 
Crosslinker Nanoparticle 
Diameter 
(nm) PDI 
ζ-Potential 
(mV) 
Pre-functionalized 311 ± 16 0.178 +25.6 ± 0.3 
Biotinylated 306 ± 12 0.155 -12.0 ± 0.2 
NP-Herc 299 ± 4 0.125 -7.1 ± 0.7 
NP-OKT9 302 ± 17 0.083 -8.3 ± 0.6 
PEG8DES 
NP-IgG 298 ± 10 0.164 -6.3 ± 0.3 
Pre-functionalized 288 ± 3 0.086 +27.3 ± 0.9 
Biotinylated 300 ± 1 0.178 -14.5 ± 0.4 
NP-Herc 303 ± 15 0.133 -15.1 ± 0.4 
NP-OKT9 294 ± 3 0.143 -14.3 ± 0.9 
PEG8DTS 
NP-IgG 297 ± 6 0.163 -15.5 ± 0.75 
 
3.1.3.2  Quantitative In Vitro Cellular Uptake 
Nanoparticle uptake was investigated in BT474 (human breast cancer) and Ramos 
(human Burkitt’s lymphoma) cells.  BT474 cells display high expression of the HER2 
receptor (human epidermal growth factor receptor 2), which is present in approximately 
30% of breast cancers.33,34  Both BT474 and Ramos cells overexpress the transferrin 
receptor (TfR).31,35  The TfR is a prevalent protein amongst a variety of cancer cells 
because it is necessary for intracellular transport of iron, which is required for DNA 
synthesis and active proliferation.36  Both the HER2 and TfR are highly amplified in 
cancerous cells relative to normal cells, and therefore, are appealing targets for cancer 
therapeutics. 
Nanoparticles composed of the silyl ether crosslinker PEG8DES were targeted 
with Herceptin and OKT9.  Herceptin (trastuzumab) is a humanized monoclonal antibody 
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developed by Genentech that is approved as an immunotherapy with breast cancer 
patients.37  It binds to the extracellular region of HER2 to inhibit tumor growth and thus, 
is a potential targeting ligand for therapies aimed at HER2-positive cancers.38,39  OKT9 is 
a monoclonal antibody that binds with the TfR, and IgG is a nonspecific, control antibody.  
Both NP-Herc and NP-OKT9, in addition to NP-IgG and pre-functionalized nanoparticles, 
were incubated with BT474 cells at various concentrations (0-200 µg/mL) for 4 h at 37 
°C.  Samples were analyzed using a flow cytometry technique to quantify the percentage 
of cells with internalized particles.40  Pre-functionalized nanoparticles internalized rapidly 
but indiscriminately into BT474 cells because of their positive surface charge.  Over 95% 
of BT474 cells readily internalized PEG8DES pre-functionalized nanoparticles at all 
particle concentrations (Figure 3.5).  Also, NP-Herc and NP-OKT9 exhibited 
nanoparticle uptake in a dose dependent manner with over 90% of BT474 cells having 
internalized nanoparticles because BT474 cells have amplified levels of both the HER2 
and TfR.  Uptake of control PEG8DES NP-IgG was much lower (<30%), owing to the 
negative ζ-potential of and nonspecific ligands on the nanoparticles.  Through attachment 
of targeting ligands to the surface of silyl ether-based nanoparticles, specific 
internalization of NP-Herc and NP-OKT9 was observed despite the negative surface 
charge of the nanoparticles.  Herceptin and OKT9 bound to the HER2 and TfR, 
respectively, to facilitate receptor-mediated endocytosis of the nanoparticles. 
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Figure 3.5  Internaliztion of nanoparticles fabricated from the PEG8DES crosslinker in 
BT474 cells. 
 
Additionally, silyl ether-based nanoparticles were functionalized with OKT9 to 
target the TfR expressed on Ramos cells.  As seen in Figure 3.6, the positively-charged 
PEG8DES base nanoparticles internalized rapidly into the cells with over 95% of Ramos 
cells having associated nanoparticles.  Approximately 90% of Ramos cells also 
internalized NP-OKT9 in a dose dependent manner, while control silyl ether-based NP-
IgG bound minimally to the cells.  NP-OKT9 bound to the TfR overexpressed in Ramos 
cells, inducing subsequent receptor-mediated endocytosis.  This demonstrates selective 
targeting of NP-OKT9 relative to NP-IgG. 
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Figure 3.6  Internalization of nanoparticles fabricated from the PEG8DES crosslinker in 
Ramos cells. 
 
In both BT474 breast cancer and Ramos Burkitt’s lymphoma cell lines, 
nanoparticles, composed of the silyl ether crosslinker PEG8DES, demonstrated in vitro 
uptake trends similar to PEG-based targeted nanoparticles.  Silyl ether pre-functionalized 
nanoparticles were internalized into both cell lines quickly but nonspecifically and in a 
dose dependent fashion due to their positive ζ-potential, as was previously observed with 
PEG-based nanoparticles.  Targeted nanoparticles, fabricated from the silyl ether 
crosslinker, selectively internalized into cells, analogous to PEG-based nanoparticles.  
Based on these results, silyl ether-based nanoparticles with surface properties similar to 
PEG-based nanoparticles exhibited comparable in vitro trends. 
 
3.1.3.3  Confocal Microscopy 
In addition to flow cytometry, targeting of silyl ether-based nanoparticles was 
visualized by confocal microscopy.  Targeted and control nanoparticles fabricated from 
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the PEG8DES crosslinker, fluorescently labeled through fluorescein o-acrylate, were 
incubated with BT474 breast cancer cells.  Shown in Figure 3.7, nanoparticle 
internalization, seen in green, was observed with NP-Herc and NP-OKT9 but minimally 
with NP-IgG.  This is indicative of the selective binding of NP-Herc to the HER2 
receptor and of NP-OKT9 to the TfR, which induces receptor-mediated endocytosis.  As 
was previously observed by flow cytometry, BT474 cells did not internalize an 
appreciable amount of NP-IgG as a result of the nonspecific ligands on the nanoparticles 
and the negative surface charge.  Confocal micrscopy images corroborated the results 
determined by flow cytometry. 
 
 
Figure 3.7  Confocal microscopy images of specific internalization of nanoparticles 
(green), fabricated from the PEG8DES crosslinker, in BT474 cells. 
DIC Particles Merge Nucleus 
NP-Herc 
NP-IgG 
NP-OKT9 
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Furthermore, the observed green fluorescence from targeted silyl ether-based 
nanoparticles differed from that in previous images of PEG-based nanoparticles.  Prior 
images of PEG-based nanoparticles consisted of prominent punctate areas of fluorescence 
from the fluorescein-labeled nanoparticles.  Instead of distinct, spotted fluorescence, 
dispersed and diffuse fluorescence was noted from nanoparticles fabricated with the 
PEG8DES crosslinker.  This difference may be attributed to the intracellular degradation 
of the silyl ether-based nanoparticles.  As demonstrated previously, microparticles 
composed of dimethyl silyl ether (DMS) degraded rapidly under intracellular conditions, 
observed as widespread fluorescence in the cell through confocal microscopy.19  So the 
susceptibility of nanoparticles, fabricated from the PEG8DES crosslinker, to acid-
catalyzed hydrolysis may be detected by confocal microscopy.  Active degradation of 
these nanoparticles stimulated by acidic intracellular conditions is a favorable property 
for nanocarriers whereby the therapeutic payload can be locally released at the site of 
disease. 
 
3.1.3.5  Cytotoxicity of Blank Silyl Ether-Based Nanoparticles 
To ensure the nontoxicity of this nanoparticulate drug delivery system developed 
from novel silyl ether biomaterials, cytotoxicity of silyl ether-based nanoparticles and 
their degradation products were investigated in BT474 (breast cancer), HeLa (human 
cervical adenocarcinoma), and H460 (human large cell lung carcinoma) cells.  Ramos 
cells were not investigated because prior studies revealed that similar PEG-based 
nanoparticles, without any drugs and targeted with OKT9, were cytotoxic to Ramos cells 
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due to the multivalent nature of the nanoparticles.31  Pre-functionalized nanoparticles, 
comprised of PEG8DES and PEG8DTS, were incubated with each cell line for 72 h at 37 
°C, after which the viability of cells was evaluated with a bioluminescence assay 
detecting ATP generation.  In all three cell lines, the pre-functionalized nanoparticles did 
not elicit significant cytotoxicity (Figure 3.8).  There was minimal difference in toxicity 
for nanoparticles fabricated from the PEG8DES and PEG8DTS crosslinkers as well.  The 
results suggest that nanoparticles fabricated from these novel silyl ether crosslinkers and 
the degradation byproducts are well-tolerated by the cells.  
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Figure 3.8  Cell viability of BT474, HeLa, and H460 cells after incubation with pre-
functionalized nanoparticles fabricated from the PEG8DES and PEG8DTS crosslinkers. 
 
To further investigate the potential of silyl ether-based nanoparticles as a drug 
delivery system, the viability of BT474 cells with targeted nanoparticles, fabricated from 
the PEG8DES crosslinker, was studied.  NP-Herc, NP-OKT9, and NP-IgG were 
incubated with BT474 cells for 72 h at 37 °C and then analyzed for cellular viability.  
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Similar to the pre-functionalized nanoparticles, the targeted versions exhibited minimal 
cytotoxicity across a range of nanoparticle concentrations (Figure 3.9).  Based on these 
results, silyl ether crosslinkers are promising materials for therapeutic targeted 
nanocarriers because their blank nanoparticle formulations and degradation byproducts 
do not exhibit cytotoxicity in a range of cancer cells and nanoparticle concentrations.  
This supports the potential for silyl ether-based nanoparticles targeted for the HER2 and 
TfR as improved drug delivery agents. 
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Figure 3.9  Cell viability of BT474 cells after incubation with targeted nanoparticles 
fabricated from the PEG8DES crosslinker. 
 
3.1.3.6  Fabrication of Silyl Ether-Based Nanoparticles Loaded with Docetaxel 
As nanoparticles fabricated from the PEG8DES and PEG8DTS crosslinkers were 
not cytotoxic in either pre-functionalized or targeted formulations and demonstrated 
intracellular degradation, silyl ether chemistry is a viable approach for biomaterials used 
in drug delivery.  To further investigate the efficacy of silyl ether-based nanoparticles as 
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drug delivery agents, they were applied to the delivery of docetaxel.  Docetaxel is a 
chemotherapeutic antimicrotubule agent, approved as Taxotere for the treatment of breast, 
non-small cell lung, prostate, gastric, and head and neck cancers.24  Docetaxel has also 
demonstrated promise over other drugs including doxorubicin and paclitaxel.41  However, 
like other chemotherapeutics, docetaxel is plagued by systemic toxicities and thus 
adverse side effects, so it is an attractive candidate for enhanced efficacy by 
encapsulation within nanocarriers. 
Docetaxel was loaded into nanoparticles, comprised of the PEG8DES and 
PEG8DTS crosslinkers, with 1 wt % by addition to the preparticle solution (Table 3.4). 
 
Table 3.4  Composition of docetaxel-containing silyl ether-based nanoparticles. 
Monomers Wt % 
PEG8DES or  PEG8DTS 86 
2-Aminoethyl methacrylate hydrochloride 10 
Fluorescein o-acrylate 2 
2,2-Diethoxyacetophenone 1 
Docetaxel 1 
 
Nanoparticles encapsulating the chemotherapeutic were fabricated following the same 
procedure as blank particles.  Addition of docetaxel did not adversely affect the formation 
of cylindrical nanoparticles by the PRINT process as seen by SEMs in Figure 3.10.  
Surface functionalization of the nanoparticles and targeting with Herceptin, OKT9, and 
IgG were also performed under the same conditions as blank nanoparticles. 
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Figure 3.10  SEMs of cylindrical 200 nm nanoparticles, fabricated from the (A) 
PEG8DES and (B) PEG8DTS crosslinkers, containing docetaxel.  Scale bar is 3 µm. 
 
3.1.3.7  Cytotoxicity of Targeted Silyl Ether Nanoparticles Loaded with Docetaxel 
Similar to other cancers, HeLa cells express amplified levels of the TfR,31 which 
was used as the target for 1 wt % docetaxel-loaded nanoparticles.  Nanoparticles were 
fabricated from the PEG8DES crosslinker, functionalized, and targeted with OKT9 and 
IgG.  They were incubated with HeLa cells for 72 h at 37 °C and evaluated for 
cytotoxicity thereafter.  Dose dependent cytotoxicity was observed for both NP-OKT9 
and NP-IgG fabricated from the PEG8DES crosslinker (Figure 3.11). 
 
(A) (B) 
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Figure 3.11  Cytotoxicity of targeted nanoparticles, fabricated from the PEG8DES 
crosslinker, loaded with docetaxel in HeLa cells. 
 
However, no difference in cytotoxicity between NP-OKT9 and NP-IgG was observed.  In 
fact, the cytotoxic profiles were nearly identical within each nanoparticle composition 
(Table 3.5). 
 
Table 3.5  IC50 values of targeted nanoparticles, fabricated from the PEG8DES 
crosslinker, loaded with docetaxel in HeLa cells. 
Nanoparticle IC50 (nM) 
NP-OKT9 5.2 × 10-4 
NP-IgG 4.8 × 10-4 
 
It was expected that NP-OKT9 would bind specifically with the TfR on the cellular 
surface of HeLa cells and internalize the nanoparticles to promote the intracellular 
degradation of the nanoparticles under acidic conditions.  It was also anticipated that 
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HeLa cells would not internalize NP-IgG because of the negative surface charge and 
nonspecific control targeting ligands on the nanoparticles.  Instead, targeting ligands on 
the nanoparticle surface did not influence the cytotoxicity in HeLa cells.  This is 
potentially because docetaxel was poorly retained within the nanoparticles.  In hydrogel 
particles, the predominant mechanism of drug release is passive diffusion.42  Thus, 
cytotoxicity observed from NP-OKT9 likely was not associated with TfR-mediated 
endocytosis and the subsequent intracellular degradation of the nanoparticles for release 
of docetaxel.  Instead, docetaxel may diffuse out of NP-OKT9 and NP-IgG, resulting in 
similar cytotoxicity profiles regardless of the targeting moieties on the nanoparticle 
surface. 
Because docetaxel was encapsulated within the nanoparticles, loss of the drug 
during surface functionalization and targeting was a concern for these bifunctional silyl 
ether-based nanoparticles.  To further understand release of docetaxel and the 
cytotoxicity profiles observed, pre-functionalized nanoparticles were fabricated from the 
PEG8DES crosslinker and loaded with 1 wt % of docetaxel.  One set of pre-
functionalized nanoparticles was set aside while another set was washed in a similar 
manner to nanoparticles undergoing functionalization and targeting.  Pre-functionalized 
nanoparticles were incubated with HeLa cells for 72 h at 37 °C and then analyzed for cell 
viability.  As seen in Figure 3.12, blank nanoparticles without any encapsulated docetaxel 
did not elicit strong cytotoxic responses over a large concentration range, suggesting the 
nanoparticle composition of PEG8DES and its degradation byproducts are well-tolerated 
by HeLa cells.  Drug-loaded pre-functionalized nanoparticles without extensive washing 
exhibited cytotoxicity at all concentrations.  However, when the same nanoparticles were 
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processed through multiple washings, they showed dose dependent toxicity.  Through 
repeated washes, encapsulated docetaxel diffused out of the silyl ether hydrogel 
nanoparticles.  This suggests that docetaxel is not well retained within the nanoparticles 
and readily diffuses out of the nanoparticles, also corroborating the minimal difference in 
cytotoxicity results observed from NP-OKT9 and NP-IgG. 
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Figure 3.12  Cytotoxicity of washed and unwashed pre-functionalized nanoparticles, 
fabricated from the PEG8DES crosslinker, loaded with 1 wt % docetaxel in HeLa cells.  
Blank (0% docetaxel) nanoparticles were dosed at the same nanoparticle concentrations 
as the drug-loaded nanoparticles. 
 
Consequently, nanoparticles fabricated from the silyl ether crosslinkers may not 
be appropriate nanocarriers for docetaxel or other small molecules therapeutics as the 
cargo freely diffuses from within the nanoparticles.  Nonethless, utilizing silyl ether 
chemistry as acid-sensitive moieties that are responsive to environmental triggers 
possesses great potential.  Instead of nanoparticles comprised of silyl ether crosslinkers, 
we exploit the sensitivity of silyl ethers for drug delivery by incorporation of the 
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functionality into a prodrug and explore its delivery through targeted nanoparticles in the 
following sections. 
 
3.1.4  Conclusions 
Bifunctional silyl ether crosslinkers PEG8DES and PEG8DTS were investigated 
as biomaterials for drug delivery nanoparticles.   The crosslinkers were used to 
successfully fabricate cylindrical nanoparticles (d = 200 nm and h = 200 nm) through the 
PRINT technology.  This reinforces the versatility of the PRINT platform as novel 
materials, including these silyl ethers, can be readily incorporated into particles.  
Furthermore, the silyl ether-based nanoparticles were functionalized with Herceptin and 
OKT9 and investigated in vitro for cellular targeting of the HER2 and TfR.  Both NP-
Herc and NP-OKT9 demonstrated specific uptake relative to control NP-IgG in BT474 
and Ramos cells, suggesting nanoparticle internalization through receptor-mediated 
endocytosis.  After internalization, targeted nanoparticles prepared from the PEG8DES 
crosslinker degraded intracellularly, as observed by diffuse fluorescence throughout the 
cells by confocal microscopy.  This indicated that the nanoparticles are responsive to the 
stimuli of acidic conditions within the cells.  Moreover, cytotoxicity of blank pre-
functionalized and targeted nanoparticles indicated that the silyl ether-based materials 
and its degradation byproducts are well-tolerated by BT474, HeLa, and H460 cells.  
Specific cellular targeting and internalization, acid-catalyzed hydrolysis, and relative 
nontoxicity of the nanoparticles are promising traits of drug delivery vehicles for cancer 
therapeutics. 
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Efficacy of the silyl ether-based nanoparticles was investigated by encapsulation 
of the chemotherapeutic agent docetaxel.  Both NP-OKT9 and NP-IgG exhibited dose-
dependent cytotoxicity but negligible differences between targeted and control 
formulations.  These results were due to poor retention of encapsulated docetaxel within 
the nanoparticles due to passive diffusion.  Loss of the therapeutic payload during the 
targeting of the nanoparticles produced less cytotoxic pre-functionalized nanoparticles as 
compared to those with less processing.  The potential of nanoparticles fabricated from 
the silyl ether crosslinkers as drug delivery vehicles is overshadowed by the rapid passive 
diffusion of docetaxel out of the nanoparticles. 
 
3.1.5  Future Work 
Although targeted nanoparticles fabricated from the bifunctional silyl ether 
crosslinkers PEG8DES and PEG8DTS were not ideal drug delivery vehicles for docetaxel, 
silyl ether-based crosslinkers still have much promise as stimuli-responsive materials for 
biomedical purposes.  The hydrogel nanoparticles may not be appropriate for the delivery 
of small molecules drugs, such as docetaxel, because of uncontrolled passive diffusion of 
the drug out of the nanoparticles, but they could be utilized for macromolecular cargoes, 
including peptides,43 proteins,44 and oligonucleotides.45  The hydrodynamic radii of 
macromolecules would promote sustained release from hydrogels instead of the rapid 
diffusion of small molecules.42  Furthermore, silyl ether crosslinkers could be utilized as 
stimuli-responsive materials for biomedical devise.  Initial investigations have been 
promising.  The previously reported DMS crosslinker was molded into rudimentary 
biomedical devices of sutures and stents; both devices showed accelerated degradation 
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under acidic conditions.19  Because silyl ether chemistry provides precise control over the 
rate of degradation, based on the substituents on the silicon atom, biomedical devices 
prepared from these materials can truly be tailored to fit the application and needs of 
patients. 
 
3.2  Nanoparticles Containing Degradable Silyl Ether Prodrugs 
 
3.2.1  Introduction 
Gemcitabine (2’,2’-difluorodeoxycytidine, dFdC, Gemzar, Figure 3.13) is a 
versatile chemotherapeutic drug with proven anticancer efficacy against a variety of 
cancers including pancreatic,46 lung,47 breast,48 ovarian, and head and neck.49  It is a 
pyrimidine nucleoside analogue that must be delivered into cells through nucleoside 
transporters (NTs) in order to inhibit cell growth.50,51 
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Figure 3.13  Chemical structure of gemcitabine. 
 
Once internalized, gemcitabine is phosphorylated by deoxycytidine kinase (dCK) to its 
monophosphate form and then further into the active diphosphate and triphosphate 
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metabolites.  The active triphosphate derivative is incorporated into DNA, inhibiting 
DNA synthesis and thus, arresting cellular growth in the early S phase.52 
Despite its clinical relevance, gemcitabine faces some challenges.  As a 
hydrophilic, polar drug, it possesses poor membrane permeability.  Similar to other 
nucleoside analogues, gemcitabine requires active transport processes via NTs for 
delivery into cells.51,53  Still another limitation of gemcitabine is that it is rapidly 
metabolized in the blood, liver, kidneys, and other organs by cytidine deaminase into the 
inactive 2’,2’-difluorodeoxyuridine, which is subsequently excreted in urine.54,55  
Therefore, gemcitabine has a short plasma half-life of only 8-17 min in humans.53,56,57  
This adversely affects the bioavailability and thus reduces the efficacy of the drug. 
Current efforts to improve upon gemcitabine have ranged from aerosols58-62 to 
conjugates63-68 to nanocarriers.54,55,69-75  In particular, gemcitabine prodrugs have been 
designed and synthesized with various lipids with the aim of protecting gemcitabine from 
rapid deamination to its inactive uridine metabolite.  Gemcitabine has been modified with 
fatty acids63,76,77 and also with saturated and monounsaturated 18-20 carbon atom 
chains64 to yield select prodrugs with higher in vitro cytotoxicity profiles than the original 
drug, in addition to reduced degradation by cytidine deaminase.  Although these 
gemcitabine prodrugs overcame the limitation of metabolizing to the inactive metabolite, 
they included their own set of challenges, namely poor aqueous solubility and problems 
with administration.53 
To address this new set of challenges, liposomes and nanoparticles have been 
utilized as drug delivery agents for gemcitabine because lipophilic derivatives of 
gemcitabine are easily encapsulated into lipophilic environments of some 
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nanocarriers.54,55,71,78  Liposomes and nanoparticles have enhanced the in vitro 
cytotoxicity of the chemotherapeutic drug through increased cellular penetration55 and 
also have improved the in vivo antitumor activity through the differential 
pharmacokinetic profiles of the small molecule drug and nanocarriers.75,78,79  Entrapping 
gemcitabine within liposomes and nanoparticles mitigated the plasma degradation and 
inactivation of gemcitabine by cytidine deaminase.54  Recent advancements involve the 
attachment of ligands specific for overexpressed cellular receptors to the surface of 
liposomes and nanoparticles to actively target cancer cells.  These studies demonstrated 
that gemcitabine encapsulated in nanoparticles that target the epidermal growth factor 
receptor (EGFR)70,71,80 or HER2 receptor69 possessed improved therapeutic effects.  
Targeted nanocarriers promoted greater intracellular accumulation of the drug than 
untargeted nanocarriers to further enhance in vitro cytotoxicity and in vivo antitumor 
activity. 
In this study, we investigated the potential of PRINT nanoparticles, targeting the 
transferrin receptor (TfR), as drug delivery agents for the enhancement of gemcitabine 
efficacy.  We have previously shown that PRINT nanoparticles, conjugated with ligands 
that bind the TfR, selectively internalized into cancer cells with amplified TfR expression 
and even exhibited cytotoxicity to Ramos (B-cell lymphoma) cells due to the multivalent 
nature of the nanoparticles.31  In addition, we have synthesized novel gemcitabine 
prodrugs (Figure 3.14), consisting of an acrylate functionality through which the prodrug 
can be covalently entrapped within the nanoparticles, and also a silyl ether functionality 
that imparts acid sensitivity such that the prodrug can degrade under endocytic 
conditions.30 
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Figure 3.14  Chemical structure of diisopropyl silyl ether prodrug. 
 
We leveraged these two approaches of targeted nanoparticles and a novel prodrug to 
improve the therapeutic effect of gemcitabine.  Our design aims to protect gemcitabine 
and enhance drug accumulation intracellularly through the targeted nanoparticles in 
addition to reducing nonspecific systemic toxicity with the acid-labile prodrug. 
 
3.2.2  Experimental 
 
3.2.2.1  Chemicals and Reagents 
Biotinylated OKT9 and isotype control mouse IgG were purchased from 
eBioscience.  UltraAvidin was purchased from Leinco Technologies.  Biotin-
poly(ethylene glycol)-succinimidyl carboxymethyl ester (5000 g/mol for PEG; NHS-
PEG5000-biotin) was purchased from Laysan Bio.  Anhydrous dimethylformamide (DMF) 
and pyridine were purchased from Acros.  Poly(ethylene glycol) dimethacrylate (1000 
g/mol for PEG; PEG1000 dimethacrylate) was purchased from PolySciences.  Acetic 
anhydride, HPLC grade water and acetonitrile, and pH 5.0 buffer were purchased from 
Fisher Scientific.  All other reagents were purchased from Sigma Aldrich. 
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3.2.2.2  Cells and Culture 
H460 cells were from ATCC.  HEK293 cells were from UNC LCCC Tissue 
Culture Facility.  H460 cells were maintained in RPMI 1640 with 10% FBS, and 
HEK293 cells were maintained in MEM alpha with 10% FBS.  All media were 
supplemented with 50 units/mL penicillin and 50 µg/mL streptomycin.  All media and 
supplements were from Gibco. 
 
3.2.2.3  Fabrication of PRINT Nanoparticles 
Cylindrical nanoparticles (d = 200 nm and h = 200 nm) were fabricated using the 
PRINT technique.  Nanoparticles were prepared from a starting monomer solution (5% 
wt/vol in DMF) consisting of 78 wt % of PEG1000 dimethacrylate, 20 wt % of 2-
aminoethyl methacrylate hydrochloride, 1 wt % of fluorescein o-acrylate, and 1 wt % of 
1-hydroxycyclohexyl phenyl ketone.  A monomer film was cast upon a sheet of 
poly(ethylene terephthalate) (PET) by spreading 90 µL of monomer solution with a 
mayer rod (#2, R.D. Specialties), and it was dried with heat using a heat gun to remove 
the solvent DMF.  The monomer film and patterned mold, provided by Liquidia 
Technologies, were laminated together under pressure (40 PSI) and then delaminated, by 
gently splitting the mold and PET, to yield a mold with filled cavities.  The filled mold 
was laminated with a fresh sheet of PET and then exposed to UV irradiation (λ = 365 nm, 
power 90 mW/cm2) for 4 min under a nitrogen purge.  The mold was removed, leaving 
nanoparticles transferred on the sheet of PET.  This was due to the higher surface energy 
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of the PET.  Cold Dulbecco’s phosphate buffered saline (DPBS; 400 µL) was placed on 
the PET, and nanoparticles were collected mechanically with a cell scraper.  The 
harvested particles were washed twice with cold DPBS by centrifugation. 
 
3.2.2.4  Fabrication of Prodrug-Loaded PRINT Nanoparticles 
The same fabrication procedure as described for blank nanoparticles was followed.  
The nanoparticles were prepared from a starting monomer solution (5% wt/vol in DMF) 
consisting of 58 wt % of PEG1000 dimethacrylate, 20 wt % of diisopropyl silyl ether 
gemcitabine prodrug, 20 wt % of 2-aminoethyl methacrylate hydrochloride, 1 wt % of 
fluorescein o-acrylate, and 1 wt % of 1-hydroxycyclohexyl phenyl ketone. 
 
3.2.2.5  OKT9/IgG Conjugation to PRINT Nanoparticles 
Nanoparticles were conjugated with OKT9 or IgG through a biotin-avidin linkage.  
Nanoparticles in anhydrous DMF (500 µL at 2 mg/mL) were reacted with 5 mg of NHS-
PEG5000-biotin in the presence of 10 µL anhydrous of pyridine; the nanoparticle 
dispersion was shaken on a vortex for 2 h.  Acetic anhydride (10 µL) was added to the 
dispersion, which was shaken for 10 min, to quench unreacted amines on the nanoparticle 
surface.  The nanoparticles were washed twice with cold DPBS by centrifugation.  
UltraAvidin (50 µL, 10 mg/mL) was added to the nanoparticles in DPBS (2 mg/mL).  
The dispersion was shaken for 1 h.  The nanoparticles were washed twice with cold 
DPBS by centrifugation.  To target the nanoparticles, 100 µL of OKT9 or IgG was added 
to the nanoparticle dispersion and was shaken for 30 min at room temperature and then 
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kept overnight at 4 °C.  The nanoparticles were washed twice with cold DPBS by 
centrifugation and then resuspended in DPBS. 
 
3.2.2.6  Physical Characterization of Nanoparticles 
Scanning electron microscopy samples were prepared by pipetting 10 µL of 
nanoparticle solution onto a glass slide.  Samples were dried and coated with 2 nm of 
gold palladium with a Cressington 108 auto sputter coater (Cressington Scientific 
Instruments).  Samples were imaged with a scanning electron microscope (Hitachi S-
4700).  The size (dynamic light scattering, DLS) and charge (ζ-potential) of the 
nanoparticles were determined for 20 µg/mL nanoparticle samples in a 1 mM potassium 
chloride solution with a Malvern Instruments Nano ZS. 
 
3.2.2.7  Quantitative In Vitro Cellular Targeting and Kinetics 
H460 cells were plated at 10,000 cells/well in a 96-well plate and allowed to 
adhere overnight at 37 °C and 5% CO2.  Nanoparticles in OPTI-MEM were incubated 
with cells at 37 °C and 5% CO2 for specified amounts of time and then removed.  The 
cells were washed twice with DPBS, trypsinized, and prepared for analysis by flow 
cytometry with a 0.2% trypan blue solution containing 10% FBS in DPBS.  Samples 
were analyzed with a Dako CyAn flow cytometer.  Similar procedures were followed for 
HEK293 cells, which were plated at 30,000 cells/well in a 96-well plate. 
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3.2.2.8  Inhibition of Nanoparticle Cellular Targeting 
H460 cells were plated at 10,000 cells/well in a 96-well plate and allowed to 
adhere overnight at 37 °C and 5% CO2.  Free OKT9 or IgG, at varying concentrations in 
complete media, was dosed onto cells.  The cells were incubated at 37 °C for 30 min, 
after which free targeting ligands were removed.  Nanoparticles in OPTI-MEM, at 200 
µg/mL, were incubated with cells at 37 °C for 4 h and then removed.  The cells were 
washed twice with DPBS, trypsinized, and prepared for analysis by flow cytometry with 
a 0.2% trypan blue solution containing 10% FBS in DPBS.  Samples were analyzed with 
a Dako CyAn flow cytometer. 
 
3.2.2.9  Kinetics of Gemcitabine Released from Nanoparticles 
Aliquots of nanoparticles loaded with prodrug were shaken in a buffer solution 
pH 7.4 or pH 5.0 at 37 °C.  At specified times, a suspension of nanoparticles was 
centrifuged to pellet the particles, and an aliquot of the supernatant was analyzed by high-
performance liquid chromatography (HPLC, Agilent Technologies Series 1200) with a 
C18 reverse phase column (Zorbax Eclipse XDB-C18, 4.6×150 mm, 5 micron).  A 
mobile phase of water and acetonitrile on a gradient of water to water:acetonitrile 
(97.5:2.5) over 15 min with a flow rate of 1 mL/min and a detection wavelength of 267 
nm was employed. 
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3.2.2.10  Qualitative In Vitro Cellular Targeting and Trafficking 
H460 and HEK293 cells were plated on cover slips in a 6-well plate (5 × 104 
cells/well) overnight at 37 °C and 5% CO2.  Cells were incubated with 50 µg/mL of 
nanoparticles in OPTI-MEM for 4 or 24 h in addition to Lysotracker Red DND-99 
(Invitrogen) at 37 °C.  Cells were fixed, made permeable with 0.1% triton-X100 in PBS 
for 3 min, and incubated with Alexa Fluor 555 phalloidin (Invitrogen) for 1 h at room 
temperature without light.  Cells were washed with DPBS, and cover slips were mounted 
onto glass slides with FluorSave Reagent (Calbiochem), and cells were imaged with a 
confocal laser scanning microscope (Olympus Fluoview FV500). 
 
3.2.2.11  Cytotoxicity of Prodrug-Loaded Nanoparticles 
H460 cells were plated at 5,000 cells/well in a 96-well plate and allowed to 
adhere overnight at 37 °C and 5% CO2.  Nanoparticles in OPTI-MEM were incubated 
with cells at 37 °C and 5% CO2 for 1 h and removed.  The cells were washed twice with 
DPBS, and complete media was added to the cells, which were incubated at 37 °C for 72 
h.  Cell viability was determined using Promega CellTiter-Glo® Luminescent Cell 
Viability Assay according to the manufacturer’s instructions.  Bioluminescence was 
measured by a SpectraMax M5 plate reader (Molecular Devices). 
 
3.2.3  Results and Discussion 
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3.2.3.1  PRINT Particle Fabrication and Conjugation with OKT9/IgG 
The PRINT technology is a robust particle fabrication approach that facilitates 
independent control over particle size, shape, matrix composition, and surface chemistry 
and has been described previously.19,25-29,31,32  Through this technique, cylindrical 
nanoparticles (d = 200 nm and h = 200 nm), primarily composed of poly(ethylene glycol) 
(PEG, 1000 g/mol) dimethacrylate, were fabricated (Figure 3.15). 
 
 
Figure 3.15  SEM of 200 nm cylindrical PRINT nanoparticles. 
 
The nanoparticles were also prepared to include 20 wt % of 2-aminoethyl methacrylate 
hydrochloride and 1 wt % of fluorescein o-acrylate (Table 3.6).    The 2-aminoethyl 
methacrylate hydrochloride provided a functional handle through which the nanoparticle 
surface could be modified.  Fluorescein o-acrylate labeled the nanoparticles to enable 
fluorescent monitoring and visualization of nanoparticles with cells. 
 
5 µm 
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Table 3.6  Composition of blank and prodrug-loaded PRINT nanoparticles. 
Monomers No Prodrug (Wt %) 
With Prodrug 
(Wt %) 
PEG1000 dimethacrylate 78 58 
2-Aminoethyl methacrylate hydrochloride 20 20 
Fluorescein o-acrylate 1 1 
1-Hydroxycyclohexyl phenyl ketone 1 1 
Diisopropyl silyl ether gemcitabine prodrug 0 20 
 
The pre-functionalized nanoparticles with no surface modification had a hydrodynamic 
diameter of 277 nm with a narrow polydispersity index of 0.037.  They were also cationic 
and possessed a positive ζ-potential (+25.6 ± 0.4 mV) due to the amine surface 
functionality (Table 3.7).  It has been shown that positively charged nanoparticles are 
internalized rapidly but nonspecifically into cells27,81-83 and can induce cytotoxicity.84  
Conversely, negatively charged particles exhibit decreased cellular uptake,27,81-83 so 
nanoparticles with a negative ζ-potential and targeting ligands can effectively circumvent 
nonspecific cellular internalization while targeting specific diseased cells.31 
 
Table 3.7  Hydrodynamic dimaeter and zeta potential of 200 nm PRINT nanoparticles. 
Nanoparticle Diameter (nm) PDI ζ-Potential (mV) 
Pre-functionalized 277 ± 4 0.037 +25.6 ± 0.4 
Biotinylated 309 ± 7 0.071 -10.0 ± 0.7 
Avidinated 304 ± 2 0.104 -5.31 ± 0.4 
NP-OKT9 310 ± 4 0.114 -15.3 ± 0.7 
NP-IgG 301 ± 3 0.085 -14.8 ± 0.8 
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Thus, the surface of the pre-functionalized nanoparticles was functionalized and 
enhanced with targeting ligands as previously described.  To evade nonspecific uptake 
into cells, the pre-functionalized nanoparticles were initially reacted with NHS-PEG5000-
biotin, followed by acetic anhydride to quench any unreacted amines.  Quenching of 
unreacted amines shifted the positive ζ-potential to negative (biotinylated nanoparticle ζ-
potential = -10.0 mV, Table 3.7) to avoid nonspecific cellular internalization.  Targeting 
ligands were then attached via biotin-avidin linkages.  Biotinylated nanoparticles were 
reacted with avidin, and thereafter, the targeting ligands (OKT9) or the control ligands 
(IgG) were conjugated to the nanoparticle surface.  OKT9 is an anti-human transferrin 
receptor monoclonal antibody, and IgG is a control mouse antibody of the same isotype.  
Both OKT9-targeted nanoparticles (NP-OKT9) and IgG-targeted nanoparticles (NP-IgG) 
maintained hydrodynamic diameters of ~300 nm and negative ζ-potentials of about -15 
mV (Table 3.7) for minimizing nonspecific cellular internalization. 
 
3.2.3.2  Quantitative In Vitro Cellular Uptake and Kinetics 
Cellular internalization of the nanoparticles without prodrug was investigated in 
H460 (human large cell lung carcinoma) and HEK293 (transformed human embryonic 
kidney) cells.  H460 cells display amplified expression of the transferrin receptor (TfR), 
in contrast to HEK293 cells that have minimal cellular levels of the receptor.31  
Transferrin binds to iron for transport through the TfR.  Thus, the TfR is critical in the 
transport of iron, which is involved in metabolism, respiration, and DNA synthesis, and 
expression of the TfR is regulated by intracellular iron levels.  Consequently, the TfR is 
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highly expressed on actively proliferating cancerous cells and at low levels on normal 
cells.  Therefore, the TfR is an attractive target for cancer treatments.36 
Pre-functionalized nanoparticles, as well as NP-OKT9 and NP-IgG, at various 
concentrations (0-200 µg/mL), were incubated with H460 and HEK293 cells at 37 °C 
over a range of times (1-8 h).  Samples were analyzed using a flow cytometry technique 
to quantify the percentage of cells with bound and internalized nanoparticles.40  When 
pre-functionalized nanoparticles were investigated with H460 and HEK293 cells, 
nanoparticles were rapidly internalized into cells in a dose dependent manner (Figure 
3.16).  In both cell lines, over 80% of cells had internalized pre-functionalized 
nanoparticles after 8 h.  In H460 cells, time-dependent nanoparticle uptake was observed, 
while minimal differences in uptake were observed amongst the incubation times for 
HEK293 cells.  Regardless of the amount of time for nanoparticle incubation, HEK293 
cells exhibited significant internalization of nanoparticles (>90%).  This rapid 
nanoparticle uptake into cells was expected as we have previously shown that PRINT 
particles with positive ζ-potential are easily internalized nonspecifically.27,83 
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Figure 3.16  Pre-functionalized nanoparticle uptake as a function of nanoparticle 
concentration and time in (A) H460 cells and (B) HEK293 cells. 
 
Despite the significant cellular internalization of pre-functionalized nanoparticles, 
positively charged particles are internalized nonspecifically27,81-83 and can induce 
cytotoxic effects.84  Consequently, the pre-functionalized nanoparticles were engineered 
to have a negative ζ-potential to evade nonspecific cellular uptake and conjugated with 
targeting ligands for the TfR to enhance selective drug delivery.  When incubated with 
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H460 cells, which have amplified expression of TfR, NP-OKT9 exhibited selective 
targeting in a nanoparticle dose and time dependent fashion.  As seen in Figure 3.17, up 
to 57% of cells had associated NP-OKT9 at 1 h.  Targeting was saturated at 4 h with 
~80% of cells with bound NP-OKT9.  In contrast, because of their negative charge and 
nonspecific ligand, NP-IgG did not exhibit an appreciable level of uptake (<7%) in H460 
cells at all nanoparticle concentrations and incubations times.  Conversely, despite a 
negative ζ-potential, the addition of the specific targeting ligand OKT9 enabled NP-
OKT9 to bind selectively to H460 cells through targeting of the TfR.  Negatively charged 
particles can override nonspecific cellular uptake, but with a targeting ligand, the 
particles can now induce specific internalization.31 
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Figure 3.17  Association of OKT9- and IgG-targeted nanoparticles in H460 cells as a 
function of nanoparticle concentration and time. 
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Additionally, targeting of NP-OKT9 and NP-IgG in HEK293 cells was 
investigated.  When NP-OKT9 were incubated with cells, low cellular binding of 
nanoparticles was observed (Figure 3.18). 
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Figure 3.18  Association of OKT9- and IgG-targeted nanoparticles in HEK293 cells as a 
function of nanoparticle concentration and time. 
 
Unlike H460 cells, HEK293 cells have low levels of TfR expression,31 so the extent of 
NP-OKT9 uptake in H460 and HEK293 correlates well to the TfR expression on the cells.  
H460 cells internalized more NP-OKT9 and also at a quicker rate than HEK293 cells 
because H460 cells have greater expression of TfR.  On the other hand, control 
nanoparticles NP-IgG exhibited similarly minimal uptake (<6%) in HEK293 cells.  The 
difference observed in cellular binding of NP-OKT9 in H460 and HEK293 cells 
demonstrate the potential of targeted nanoparticles to preferentially bind and internalize 
into diseased cells for specific delivery of the therapeutic payload. 
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3.2.3.3  Inhibition of Nanoparticle Cellular Targeting 
To confirm binding and uptake of NP-OKT9 in H460 cells, competition with free 
targeting ligand was investigated.  H460 cells were incubated with varying concentrations 
of free OKT9 prior to exposure to nanoparticles without prodrug so that the TfR on the 
cellular surface could be bound by free ligands thereby decreasing those available to bind 
with targeted nanoparticles.  H460 cells dosed with free OKT9 exhibited lower binding 
with NP-OKT9 in a concentration dependent manner.  An increased concentration of free 
OKT9 led to greater inhibition in binding of NP-OKT9 (Figure 3.19). 
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Figure 3.19  Inhibition of binding of NP-OKT9 to H460 cells by free targeting antibodies. 
 
Targeting was suppressed to <20% when cells were exposed to 200 µg/mL of free OKT9 
before incubation with NP-OKT9.  Binding of NP-OKT9 was inhibited in a dose-
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dependent manner with free OKT9, but addition of the nonspecific IgG isotype control 
antibody to H460 cells did not influence binding of NP-OKT9.  The selective binding of 
NP-OKT9 and its suppression only with free OKT9 indicate that the targeted 
nanoparticles are specifically targeting the TfR for subsequent internalization through 
transferrin receptor-mediated endocytosis.  As such, highly specific NP-OKT9 targeted 
for the TfR demonstrate potential as drug delivery vehicles to enhance therapeutic 
efficacy. 
 
3.2.3.4  Kinetics of Gemcitabine Released from Nanoparticles 
Novel asymmetric bifunctional silyl ether prodrugs of gemcitabine were reported 
previously from our group.30  Silyl ether chemistry is ideal for the synthesis of various 
prodrugs as silyl ethers are acid sensitive20 and degrade under acidic environments within 
the body.  Moreover, the rate of degradation of these prodrugs and subsequent release of 
the drug are tunable by modifying the substituents on the silicon atom.  Further, 
degradation of these prodrugs releases the parent drug without any trace of chemical 
modification.  For these reasons, novel asymmetric bifunctional silyl ether prodrugs of 
gemcitabine were synthesized and incorporated into PRINT nanoparticles.30  The stability 
of each prodrug of gemcitabine was investigated under neutral (pH 7.4) and acidic (pH 
5.0) environments.  Each derivative exhibited more rapid degradation and subsequent 
release of gemcitabine under acidic conditions compared to pH 7.4 due to the silyl ether 
functionality.  Additionally, it was shown that gemcitabine prodrugs with less steric bulk 
around the silicon atom were more sensitive to acid, so prodrugs with tert-butyl groups 
were very stable relative to those with isopropyl or ethyl moieties.  The diethyl silyl ether 
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gemcitabine prodrug degraded rapidly within hours while the diisopropyl derivative 
exhibited sustained released over several days.  This demonstrates that the release of 
gemcitabine can be controlled based upon the substituents on the silicon atom. 
The diisopropyl silyl ether gemcitabine prodrug (Figure 3.14) was incorporated 
into our TfR-targeted nanoparticulate system because it demonstrated sensitivity to acidic 
conditions as well as extended release of the chemotherapeutic over several days.30  
Gemcitabine is also hydrophilic and highly soluble in water, so it is difficult to retain the 
drug within hydrogel nanoparticles because rapid and significant loss of the drug would 
likely occur in aqueous environments.53  Thus, recent efforts by others involved 
encapsulating lipophilic derivatives of the drug into hydrophobic pockets of liposomes54 
or nanoparticles.55,71,78  Our novel silyl ether gemcitabine prodrug circumvented the issue 
of loss in aqueous environments through its acrylate functionality which allowed the 
prodrug to be covalently conjugated into the nanoparticle to avoid loss of the cargo by 
diffusion while the silyl ether moiety enabled the controlled release of gemcitabine. 
Targeted nanoparticles, loaded with the silyl ether gemcitabine prodrug, were 
incubated in physiological (pH 7.4) or endocytic (pH 5.0) environments at 37 °C to 
investigate the effect of targeting on the prodrug as well as the degradation of the prodrug 
and subsequent release of gemcitabine.  Supernatants from aliquots of nanoparticle 
suspensions were analyzed by high-performance liquid chromatography (HPLC).  As 
seen in Figure 3.20, gemcitabine was released from targeted nanoparticles more rapidly 
under an acidic environment than under a neutral pH. 
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Figure 3.20  Release of gemcitabine from targeted nanoparticles loaded with silyl ether 
prodrug at acidic (5.0) and neutral (7.4) pH over time. 
 
Based on this data, the half-life of drug release from targeted nanoparticles at pH 5.0 was 
15 days, whereas the half-life at pH 7.4 was 381 days.  Rapid release of gemcitabine from 
the targeted nanoparticles was derived from the silyl ether functionality in the prodrug.  
Silyl ether moieties are known to be susceptible to acid.20  The more rapid release of 
gemcitabine from nanoparticles under endocytic conditions also demonstrated that 
functionalizing the surface of the nanoparticles with targeting ligands did not adversely 
influence the behavior of the silyl ether prodrug.  The differential and more rapid 
degradation rate of the silyl ether prodrug and consequent release of gemcitabine from 
targeted nanoparticles under endocytic environments demonstrate the possibility of an 
engineered drug delivery system to specifically deliver the drug intracellularly and thus 
improve bioavailability. 
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3.2.3.5  Qualitative In Vitro Cellular Uptake and Trafficking 
Targeting of NP-OKT9 without prodrug with H460 cells was also visualized by 
confocal microscopy, through which intracellular accumulation of nanoparticles in acidic 
vesicles was observed.  Inside these acidic compartments, prodrug degradation can be 
activated for release of gemcitabine from nanoparticles.  Cells were treated with 
fluorescein-labeled nanoparticles.  As expected, NP-OKT9 were associated with H460 
cells through specific targeting of OKT9 to the TfR, while NP-IgG did not bind to the 
cells (Figure 3.21). 
 
 
Figure 3.21  Confocal microscopy images of specific targeting of NP-OKT9 (green) and 
minimal association of NP-IgG with H460 cells. 
 
To investigate the intracellular fate of NP-OKT9, H460 cells were treated with NP-OKT9 
and Lysotracker Red, which labels acidic vesicles within cells.  NP-OKT9 were found to 
bind the TfR, internalize into H460 cells, and colocalize with Lysotracker Red, indicating 
Particles Lysotracker Red DAPI Merge 
4 h 
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24 h 
NP-IgG 
 143 
that after internalization, NP-OKT9 accumulated into acidic compartments, such as 
endosomes and/or lysosomes, of the cells (Figure 3.22). 
 
 
Figure 3.22  Confocal microscopy images of specific targeting of NP-OKT9 (green) and 
intracellular trafficking into acidic compartments (red) in H460 cells. 
 
The intracellular pathway of internalized targeted nanoparticles may be similar to 
that of the TfR with transferrin.  As the mechanism for iron delivery, the TfR does not 
undergo the endosome-lysosome pathway so as to avoid degradation of the TfR.  Instead, 
it is recycled back to the plasma membrane following internalization.36  Intracellular TfR 
are incorporated into endocytic vesicles that interact transiently with EEA1 (early 
endosome antigen 1)-enriched endosomes and then move into juxtanuclear recycling 
compartments free of EEA1.85  As seen in Figure 3.22, the targeted nanoparticles 
internalized through receptor-mediated endocytosis and accumulated in acidic vesicles 
intracellularly.  This is consistent with results observed previously in Ramos cells where 
TfR-targeted nanoparticles internalized into acidic environments free of EEA1.31  
Targeted PRINT nanoparticles were endocytosed through the TfR into acidic 
compartments.  As prodrug-loaded nanoparticles released gemcitabine more rapidly 
under acidic conditions than a neutral pH (Figure 3.20), acidic vesicles within cells are 
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the preferred sites of accumulation where prodrug degradation can be triggered for drug 
release.  Effective delivery of gemcitabine can be achieved through this approach of 
combining both an acid-sensitive prodrug and targeted nanoparticles. 
 
3.2.3.6  Cytotoxicity of Prodrug-Loaded Nanoparticles 
Nanoparticles were fabricated with the diisopropyl silyl ether gemcitabine 
prodrug through the PRINT process by which the prodrug was polymerized into the 
nanoparticle.  Covalently reacting the prodrug into the nanoparticles enabled convenient 
incorporation and retention of a water soluble drug into a hydrogel matrix.  As the 
prodrug is sensitive to acid, gemcitabine was released from the nanoparticles more 
rapidly under endocytic conditions than a neutral environment.  Through targeting the 
TfR, NP-OKT9 were found to accumulate intracellularly in acidic vesicles where the 
degradation of the prodrug can be stimulated.  To investigate intracellular degradation of 
the prodrug in vitro and subsequent release of gemcitabine, cytotoxicity of prodrug-
loaded nanoparticles was evaluated by a bioluminescence assay detecting ATP generation.  
Nanoparticles were incubated with H460 cells for 1 h at 37 °C for nanoparticles to target 
and bind to cells.  Unbound nanoparticles were removed so as to minimize nonspecific 
cytotoxicity from the degradation of the prodrug and subsequent release of the drug from 
the nanoparticles.  Viability of the cells was determined after 72 h.  As shown in Figure 
3.23, NP-OKT9 and unmodified pre-functionalized nanoparticles both exhibited similar 
cytotoxicity profiles. 
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Figure 3.23  Cytotoxicity of gemcitabine and nanoparticles loaded with silyl ether 
prodrug in H460 cells. 
 
Both sets of nanoparticles were cytotoxic in subnanomolar concentrations, and the IC50 of 
NP-OKT9 (0.018 nM) was nearly three times less toxic than pre-functionalized 
nanoparticles (Table 3.8).  For NP-OKT9, cytotoxicity stemmed from the specific 
binding of OKT9 to the TfR and the subsequent receptor-mediated endocytosis of the 
nanoparticles into acidic vesicles within the cells where prodrug degradation could occur.  
Likewise, the pre-functionalized nanoparticles exhibited a similar cytotoxic profile (IC50 
= 0.0064 nM) to NP-OKT9, but instead, they internalized quickly albeit indiscriminately 
due to their positive ζ-potential.  Although the pre-functionalized nanoparticles exhibited 
a similar cytotoxicity profile to NP-OKT9, targeted nanoparticles with a negative surface 
charge are a more ideal therapeutic for in vivo purposes, as indicated by the NCI 
Nanotechnology Characterization Laboratory’s criteria for the model nanoparticle 
therapeutic. 
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Table 3.8  IC50 values of gemcitabine and PRINT nanoparticles loaded with silyl ether 
gemcitabine prodrug in H460 cells. 
 
IC50 (nM) Relative Response 
Pre-functionalized Nanoparticles 6.37 × 10-3 1.00 
NP-OKT9 1.82 × 10-2 2.86 
Gemcitabine 4.09 × 104 6.42 × 106 
 
Moreover, NP-OKT9 and pre-functionalized nanoparticles demonstrated far 
improved efficacy relative to free gemcitabine.  Gemcitabine was six orders of magnitude 
less cytotoxic than pre-functionalized nanoparticles.  The chemotherapeutic is 
categorized as an antimetabolite.  It is a nucleoside analog that once internalized, inhibits 
DNA synthesis, thereby arresting cell growth that leads to apoptosis.52  Therefore, the 
efficacy of gemcitabine is foremost dependent on its transport into cells.  The 
chemotherapeutic is typically internalized into cells through nucleoside transporters 
(NTs).50,51  In our system, the mechanism of internalization of gemcitabine was different.  
The drug was shielded from the usual cellular uptake mechanism through incorporation 
into a nanoparticulate drug delivery system.  Uptake of gemcitabine was dictated by the 
nanoparticles.  Positive pre-functionalized nanoparticles were internalized nonspecifically 
because of their positive ζ-potential and were previously shown to traffick into cells 
through clathrin- and caveolae-mediated endocytosis.27  NP-OKT9 were delivered 
intracellularly into cells through TfR-mediated endocytosis rather than NTs.  Targeted 
nanoparticles trafficked into acidic compartments where the low pH environment 
promotes rapid degradation of the silyl ether prodrug and subsequent release of 
gemcitabine.  Despite the lower concentration of dosed drug, the nanoparticles exhibited 
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well improved potency over free gemcitabine as a result of the method of delivery and 
internalization.  Studies have shown that incorporating lipophilic gemcitabine derivatives 
into liposomes and polymeric nanospheres can magnify the effectiveness of the 
drug.54,55,75,78,79  A few have also investigated nanocarriers targeting the EGFR70,71,80 and 
HER2 receptor,69 and demonstrated enhanced performance of gemcitabine through 
targeting.  NP-OKT9 make up a new class of advanced drug delivery agents that are 
responsive to environmental stimuli and can selectively target diseased cells with 
amplified expression of the TfR.  Bypassing the usual influx mechanism of NTs greatly 
enhanced the efficacy of gemcitabine when the chemotherapeutic was incorporated into 
TfR-targeted nanoparticles as an acid-sensitive prodrug that degraded under endocytic 
conditions. 
 
3.2.4  Conclusions 
TfR-targeted nanoparticles with diisopropyl silyl ether gemcitabine prodrug were 
shown to be more efficacious in vitro than gemcitabine alone, suggesting that NP-OKT9 
are a promising platform for drug delivery.  Nanoparticles demonstrated improved 
therapeutic efficacy through active targeting with OKT9 and the acid-sensitive silyl ether 
gemcitabine prodrug.  They specifically targeted H460 cells, which have high expression 
of the TfR, and thus induced receptor-mediated endocytosis for internalization of the 
nanoparticles.  Additionally, targeted nanoparticles loaded with the prodrug demonstrated 
preferential release of gemcitabine under acidic conditions compared to a neutral pH, 
indicating that the silyl ether prodrug was unaffected by incorporation into nanoparticles 
and the processing to conjugate targeting ligands.  Intracellular accumulation of NP-
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OKT9, through TfR-mediated endocytosis, into acidic vesicles promotes the acid 
catalyzed degradation of the silyl ether prodrug to release gemcitabine.  The efficacy of 
these targeted nanoparticles was investigated through cytotoxicity studies.  Targeted 
nanoparticles exhibited far improved therapeutic potency with a significantly lower IC50 
than gemcitabine alone.  This is because the usual cellular uptake mechanism of 
gemcitabine was bypassed through targeting, and an acid-sensitive silyl ether 
gemcitabine prodrug, capable of degradation under acidic environments, was employed.  
NP-OKT9 are effective drug delivery agents that can specifically target cancer cells and 
deliver its cargo intracellularly to achieve enhanced therapeutic potency.   
 
3.2.5  Future Work 
NP-OKT9 have demonstrated the potential to advance cancer therapy.  
Nanoparticles conjugated with OKT9 can target a variety of cancers that have amplified 
levels of the TfR.  When loaded with a silyl ether gemcitabine prodrug, they 
demonstrated enhanced efficacy against H460 large cell lung cancer cells in vitro.  Thus, 
they are promising drug delivery nanocarriers that may improve upon conventional 
chemotherapeutics.  NP-OKT9 were engineered and fabricated to shield gemcitabine to 
limit systemic distribution and consequently nonspecific toxicities, in addition to 
protecting the drug from potential plasma degradation.  They were also designed to 
enhance the bioavailability of gemcitabine through targeting so as to increase drug 
efficacy.  In vivo studies are required to better understand these behaviors of the targeted 
nanoparticles and the degradation of the silyl ether prodrug. 
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Moreover, TfR-targeted nanoparticles loaded with silyl ether gemcitabine 
prodrugs may be a possible therapeutic for gemcitabine-resistant cancers.  Gemcitabine is 
typically internalized into cells through nucleoside transporters (NTs), in particular the 
human equilibrative nucleoside transporter 1 (hENT1).51,52  Studies have shown that cells 
deficient in hENT1 are highly resistant to gemcitabine.50  Without hENT1, cells have 
difficulty internalizing nucleoside analogs, so the expression level of hENT1 is a 
predictive marker for cellular sensitivity to gemcitabine.50,51,53  As NP-OKT9 are 
internalized via receptor-mediated endocytosis, hENT1 would not be necessary for 
chemotherapy uptake and the usual internalization mechanism would be circumvented.  
Further investigation into targeted uptake and efficacy of nanoparticles loaded with silyl 
ether gemcitabine prodrugs in drug-resistant cells would provide more insight. 
Furthermore, the possibility of acid-sensitive silyl ether prodrugs is not limited to 
gemcitabine.  Derivatives of camptothecin and dasatinib have been synthesized and 
reported.30  Additional chemotherapeutics can be modified with silyl ether chemistry to 
create prodrugs designed to degrade under endocytic conditions.  The possibilities of silyl 
ether chemistry and its adaptation for prodrugs are still largely undiscovered.  As the 
PRINT process is amenable to fabricating particles from new materials, novel silyl ether 
prodrugs can be easily incorporated into particles for drug delivery carriers that may 
improve upon current chemotherapeutics.  Together silyl ether prodrugs and the PRINT 
platform have the potential to address a multitude of cancers. 
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